

The logo for the NK 2013 meeting is a 3x3 grid of squares. The top row contains the letters 'NK' in a light blue, 3D-style font, followed by two dark blue squares. The middle row contains a light blue square, the number '20' in a light blue, 3D-style font, and a dark blue square. The bottom row contains a light blue square, a dark blue square, the number '13' in a light blue, 3D-style font, and a dark blue square.

NK 2013

# 14th Meeting of the Society for Natural Immunity

September 18-22, 2013  
Heidelberg, Germany

## program

# Content

Welcome	3
General information	5
Sponsors	7
Fellowship recipients	8
Program	9
List of posters	14
Participant index	20
Map	31
Program at a glance	32

## Scientific Organizing Committee

**Michael Caligiuri**, Ohio State University, Columbus, OH, USA

**Mary Carington**, NCI, Frederick, MD, USA

**Mariapia Degli-Esposti**, Lyons Eye Institute, Perth, Australia

**Katharine Hsu**, Memorial Sloan-Kettering Cancer Center, NY, USA

**Stipan Jonjic**, University of Rijeka, Rijeka, Croatia

**Lewis Lanier**, University of California, San Francisco, CA, USA

**Hans-Gustaf Ljunggren**, Karolinska Institute, Stockholm, Sweden

**Eric Long**, NIH, Rockville, MD, USA

**Ofer Mandelboim**, Hebrew University, Jerusalem, Israel

**Ashley Moffett**, University of Cambridge, Cambridge, UK

**Alessandro Moretta**, University of Genoa, Genoa, Italy

**David Raulet**, University of California, Berkeley, CA, USA

**Akira Shibuya**, University of Tsukuba, Tsukuba, Japan

**André Veillette**, IRCM, Montreal, Quebec, Canada

**Eric Vivier**, Centre d'Immunologie de Marseille-Luminy, France

**Wayne Yokoyama**, Washington University, St. Louis, MO, USA

**Laurence Zitvogel**, Institut Gustave Roussy (IGR), Villejuif, France

## Local Organizing Committee

**Carsten Watzl**, IfADo, Dortmund, Germany

**Adelheid Cerwenka**, DKFZ, Heidelberg, Germany

**Alexander Steinle**, Goethe-University Frankfurt am Main, Frankfurt, Germany

**Joachim Koch**, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany

## Dear colleagues,

It is my great pleasure to welcome you to NK2013 - the 14th Meeting of the Society for Natural Immunity. This conference series has a great tradition and the organizing committee is very proud that we got the chance to host it for the first time here in Germany. In recent years the NK cell community in Germany has been growing. It all started with a very small NK cell symposium in 2006, which took place in an old villa here in Heidelberg. Since then we founded the study group "NK Cell Biology" within the German Society for Immunology and we organize annual NK cell symposia.

When we planned this event, we wanted to continue the tradition of the Society for Natural Immunity conference series, but also incorporate some new aspects in order to develop this meeting further:

- We have almost twice as many short talks than invited speakers. This way we hope to present to you the most recent and up to date developments in the field of NK cell biology. Additionally, this is a great opportunity for young researchers to present their work. Every abstract was reviewed by at least two members of the scientific organizing committee. Short talks were selected based on this review, also keeping in mind that there should be only one talk per laboratory.
- We organize a 'meet the speakers' lunch. During this event about 4 students will sit together with an invited speaker at an informal lunch event. Here, the students can discuss their data with an expert, chat about science, find a future postdoc position in a great lab or simply enjoy the good food in a historic restaurant near the meeting venue.
- We have two 'educational' sessions in the program. One on mathematical modeling and one career session for young scientists. Our special thanks goes to Ramit Mehr, who initiated and organized these sessions.
- We are proud to present a workshop on 'NK cells in clinical application: experiences and perspectives', which is free to all registered meeting participants and will take place on the day before the conference. Our thanks goes to Miltenyi Biotech for organizing and funding this event.
- We did include some well-deserved free time in the program. Please use this time to discuss ongoing and future collaborations with your friends and colleagues, find new collaboration partners or simply go for a stroll through the old town of Heidelberg.

I would like to thank SNI for giving us the opportunity to organize this event here in Heidelberg and all members of the scientific organizing committee for their help in selecting the speakers. Special thanks goes to my colleagues of the organizing committee, Adelheid Cerwenka, Joachim Koch and Alexander Steinle for all their work. The organization of this meeting would have been impossible without the administrative support of Mina Sandusky and Doris Teutsch! Thank you so much for all your great work!

Ultimately, none of these things can create a great meeting if the science is missing. So now it is up to you to fill the framework we have provided with science, presentations and discussions. This way we will have another great SNI meeting ahead of us.

I wish all of you a pleasant stay and an exiting and productive meeting.

## **Carsten Watzl**

*President of the Organizing Committee*

*Organizing Committee:*

**Adelheid Cerwenka**, DKFZ, Heidelberg, Germany

**Alexander Steinle**, Goethe-University Frankfurt am Main, Frankfurt, Germany

**Joachim Koch**, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany

**Dear all,**

On behalf of the Society for Natural Immunity (SNI), I wish to welcome you all to our 14th NK cell meeting here in beautiful Heidelberg, Germany. Held approximately every 18th months, these NK cell meetings have been the venue where most of all the exciting developments in NK cell biology have been presented for the first time. With many of the leading NK cell scientists in the world being present here, I suspect this meeting will be no different.

The SNI meetings are usually organized by local committees who find and book a suitable venue as well as perform all of the complex logistics of planning, organizing, and hosting an international meeting. We have been fortunate to have had many different organizers in the past who have hosted outstanding meetings in wonderful places all over the world, reflecting the international community of NK cell scientists. Despite the international flavor, SNI meeting organizers, all of them volunteering their time and effort, have been able to keep down the costs of our meetings. To all of them, the SNI is eternally grateful.

But right now we are most grateful to our current organizing committee, led by Carsten Watzl, who has done an outstanding work together with his co-organizers Heidi Cerwenka, Alexander Steinle and Joachim Koch. This meeting could not have happened without their tireless efforts. Thanks to them, and also to our generous sponsors, we can look forward to yet another exciting meeting.

The SNI also wish to extend a special thanks to Rolf Kiessling for providing a keynote lecture. Rolf was a true pioneer in the field of NK cells back in the early 1970ies and not only co-discovered (with Ron Herberman and his team at the NIH), but also named the cells. We very much look forward towards his exciting story. Thanks also to all our invited speakers for accepting their invitations. Finally, I would also like to thank Barb Klewien for her continued efforts on behalf of the SNI since its inception.

Many of us have over the years attended many NK cell meetings. However, a few of you are attending this meeting for the first time. I'd like to extend a special welcome to you.

The SNI thank you all for coming!

Stockholm, in September 2013

***Hans-Gustaf Ljunggren***

*President of the SNI*

# General information

## Meeting location and contact

The meeting takes place in the lecture building 'Neue Universität' of the University Heidelberg (Address: Universitätsplatz, 69117 Heidelberg, Germany).

The meeting and registration office is located directly on the ground floor in the entry hall. Please contact the registration desk upon arrival to collect your name tag and other documents. Please wear your name tag at all times during the meeting.

You can reach the registration desk by cell phone at the following number: +49 177 456 9745.

## Oral presentations

We would ask all presenters to strictly adhere to the time slot of their talk (15 minutes plus 5 minutes discussion for invited talks; 9 minutes plus 3 minutes discussion for short talks). We will provide Windows and Apple computers with the necessary software. If you present in the morning session, please hand in your presentation at the registration desk by the afternoon of the day prior to your presentation for uploading. If you present in the afternoon, please hand in your presentation during the morning.

## Poster presentations

Poster boards have the following dimensions: 1 m wide, 2 m high. Please prepare your posters accordingly (portrait orientation!). Poster boards are distributed throughout the hallways on the first and second floor of the lecture building and in lecture halls number 3 and 4a on the ground floor. All boards are labeled with the abstract number of the poster. Please mount your poster on the first day of the conference. Mounting material will be provided at the registration desk upon check in. Posters are displayed throughout the entire conference and should be taken down on the evening of Saturday, Sept. 21st.

There will be two poster sessions:

### Poster Session 1:

Thursday, Sept. 19th, 19.30 – 21.30 h  
presentation of odd numbered abstracts

### Poster Session 2:

Friday, Sept. 20th, 19.30 – 21.30 h  
presentation of even numbered abstracts

Both poster sessions include an 'open bar' with free wine, beer and soft drinks.

## Catering

Included in the registration fee are all coffee breaks, lunches and dinners (note that some late registrations do not include the gala dinner!). Coffee and dinner will be served on the ground floor of the lecture building and in the tents in the courtyard. Please wear your nametag as your ticket.

Lunch will be provided in a cafeteria (mensa) directly next to the lecture building. Please refer to the map on the last page for location. You received three lunch coupons during check in. Please use these coupons to pay for your lunch (incl. drink).

## Meet the speaker lunch

Students who signed up for the 'meet the speaker' lunch will get a ticket for the event during check in. The lunch will be provided at the restaurant "Weisser Bock" (please refer to the map on the last page for location). Please go to the restaurant immediately after the last morning session.

## Educational sessions

Two educational sessions are included in the program.

### Modeling and Simulation in NK Cell Research

Mathematical modeling and computer simulations are powerful tools which are increasingly used by immunologists to analyze cellular and molecular data, quantitatively test hypotheses and suggest new research directions. This tutorial session will present the basic principles of modeling, using examples from the NK cell field - from cell population dynamics and repertoire formation, down to modeling the molecular interactions underlying NK cell signaling.

### Career Session for Young Scientists

In today's competitive research environment, where one must publish well, secure funding and balance a demanding and mobile career with personal life, those choosing a career in life sciences would benefit from an open discussion with people who have already "made it" in the field. This session will be organized as a panel, where each of the panelists - Katharine Hsu, David Raulet, Petter Hoglund and Ramit Mehr - will present in about 10 minutes the most important advice they can give to younger researchers, and then the session will be open for questions from the audience and open discussion of the challenges facing life scientists today.

## Gala Dinner

The gala dinner on Saturday, Sept. 21<sup>st</sup> will take place in the historic castle in Heidelberg, starting with a reception at 19.00h. You can either walk up to the castle, or use the funicular (Bergbahn). Please refer to the map on the last page for the location of the funicular. The funicular runs from 18.30 – 19.15 for the transport to the castle and from 0.00 – 1.15 for transport from the castle. Your nametag works as a ticket. Registered participants will receive a ticket for the gala dinner upon check in for the conference.

## Internet Access

Free wireless internet access is available in the lecture building.

WiFi network: Uni webaccess

User id: rl1

password: gast 03

# quality meets quantity

## Get your free vericyte® NK-Cell Growth Medium sample!

Come and visit us at our booth.

Ask also for our high quality vericyte® Primary NK Cells!

[www.mediccyte.com](http://www.mediccyte.com)

medicyte GmbH . Im Neuenheimer Feld 581 . 69120 Heidelberg . Germany





## Advance and translate your NK cell research.

### Solutions from bench to bedside


- Cell separation
- Cell culture
- Cell analysis
- Clinical applications

► [miltenyibiotec.com](http://miltenyibiotec.com)

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the MACS Logo are registered trademarks of Miltenyi Biotec GmbH. Copyright © 2013 Miltenyi Biotec GmbH. All rights reserved.

## BD LSRFortessa™ X-20 with BD reagents

A brilliant new approach to multicolor cell analysis on the benchtop.



**BD Biosciences**  
 Tullastraße 8-12  
 69126 Heidelberg  
 Tel.: +49 (0) 6221 305-0  
[bdbiosciences.com/eu](http://bdbiosciences.com/eu)



BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2013 BD. A067-00

We would like to thank the following sponsors for their support:

Gold Sponsor



Silver Sponsor



Miltenyi Biotec



BD



BioLegend

The path to legendary discovery™

Dinner Sponsor



innate pharma  
the innate immunity company

Session Sponsor



Novo Nordisk®

Support Sponsor



A Brilliant Harvest

BioLegend offers seven spectrally distinct fluorophores for the violet laser, conjugated to the widest selection of anti-human and mouse antibodies.

- **More Dyes and More Targets.** 350+ antibody conjugates available.
- **You like BV421™, now you'll love BV510™.** Brilliant Violet 510™ is a novel non-tandem polymer that serves as a distinctly brighter alternative to comparable dyes.
- **More 100 test sizes.** Greater volume and value.
- **Superior performance.** Increased assay sensitivity compared to spectrally equivalent fluorophores.

Learn more at: [biolegend.com/brilliantviolet](http://biolegend.com/brilliantviolet)

Brilliant Violet™ products are trademarks of Sirigen.

BioLegend is ISO 9001:2008 and ISO 13485:2003 Certified



BioLegend®

Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343)  
Tel: 858.768.5800  
[biolegend.com](http://biolegend.com)

08-0029-13

World-Class Quality | Superior Customer Support | Outstanding Value

## Fellowship recipients

The following students have been awarded a travel fellowship.

Congratulations!

**Eva Bär**, Institute for Microbiology, Zürich, Switzerland

**Yotam Bar-On**, Hebrew University, Jerusalem, Israel

**Joshua Brandstadter**, Duke University, Durham, USA

**Chelsea Davidson**, University of Alberta, Edmonton, Canada

**Zachary Davis**, Rush University Medical Center/ University of Minnesota, Chicago, USA

**Monika Enqvist**, Karolinska Institutet, Stockholm, Sweden

**Leslie Fogel**, Washington University in St. Louis School of Medicine, St. Louis, USA

**Matthew Gumbleton**, SUNY Upstate Medical University, Syracuse, USA

**Martin Ivarsson**, Karolinska Institutet, Stockholm, Sweden

**Vanda Juranic Lisnic**, School of Medicine, University of Rijeka, Rijeka, Croatia

**Jenny Karo**, MSKCC, NEW YORK, USA

**Zena Khaznadar**, Institut universitaire d'hématologie - INSERM UMR940, Paris, France

**Jens Kieckbusch**, University of Cambridge, Cambridge, United Kingdom

**Joanna Kritikos**, Karolinska Institutet, Stockholm, Sweden

**Merlin Luetke-Eversloh**, Deutsches Rheuma-Forschungszentrum, Berlin, Germany

**Manuela Moraru**, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**Luis Alberto Perez Quintero**, Institute de recherches cliniques de Montreal, Montreal, Canada

**Biancamaria Ricci**, Sapienza - University of Rome, Rome, Italy

**Jamie Schafer**, Harvard University, Southborough, USA

**Jeffrey Teoh**, University of Virginia, Charlottesville, USA

Funding for the travel fellowships was provided by EFIS and the DFG.



**DFG** Deutsche  
Forschungsgemeinschaft

**European Federation of  
Immunological Societies**

# Program

Tuesday, September 17<sup>th</sup>

12.00 – 17.00 Registration

<b>13.00 – 18.30</b>	<b>Clinical Workshop “NK cells in clinical application: experiences and perspectives”</b>	
13.00	Carsten Watzl	<b>Welcome</b>
<b>Part 1</b>	<b>Chairs: Andrea Velardi, Perugia, Italy Wing Leung, Memphis, USA</b>	
13.10	Ulrike Koehl Hannover, Germany	<b>NK cells and tumour immune escape</b>
13.30	Christian Kalberer Basel, Switzerland	<b>Cellular immunotherapy of hematopoietic malignancies with multiple mega doses of good manufacturing practice expanded human natural killer cells</b>
13.50	Evren Alici Stockholm, Sweden	<b>Strategies to restore and activate NK cell function in cancer</b>
14.10	Jan Spanholtz Nijmegen, The Netherlands	<b>NK cell immunotherapy against AML using CD34+ derived NK cells</b>
14.30	Dean Lee Houston, TX, USA	<b>Clinical translation of ex vivo NK cell expansion with membrane-bound IL-21</b>
14.50	Jeff Miller Minneapolis, MN, USA	<b>The power of NK cells for cancer treatment – the Minnesota experience</b>
15.10 – 15.50	Coffee break	
<b>Part 2</b>	<b>Chairs: Jeff Miller, Minneapolis, MN, USA Rupert Handgretinger, Tübingen, Germany</b>	
15.50	Mark Lowdell London, UK	<b>Two-stage priming of allogeneic Natural Killer cells for the treatment of patients with acute myeloid leukaemia; a phase I/II trial</b>
16.10	Lutz Uharek Berlin, Germany	<b>Adoptive Transfer of allogeneic NK cells following haploidentical stem cell transplantation (haploSCT): results of a phase-I/II study</b>
16.30	Hans-Georg Klingemann Boston, MA, USA	<b>Overcoming Challenges in Cancer Treatment with Natural Killer Cells</b>
16.50	Antonio Curti Bologna, Italy	<b>Adoptive immunotherapy with haploidentical KIR-L mismatched natural killer cells as post-remission consolidation strategy in elderly high risk acute myeloid leukemia patients</b>
17.10	Wing Leung Memphis, TN, USA	<b>NK cell immunotherapy for treatment of pediatric malignant diseases</b>
17.30	<b>Round table discussion</b>	

## Wednesday, September 18<sup>th</sup>

09.00 – 18.00 Registration

### 14.15 – Opening Session 15.30 Chair: Angela Santoni

14.15	Carsten Watzl	Welcome and Introduction
	Hans-Gustaf Ljunggren	SNI Presidential Welcome
	Angela Santoni	In memory of Ronald Herberman
14.30	Rolf Kiessling	Keynote Lecture: “A historic overview about the discovery of NK cells and the early days of NK cell research.” (#01)

15.30 – 16.00 Coffee Break

### 16.00 – Session 1 “NK cell education, development and differentiation” 17.30 Chairs: John Trowsdale, Werner Held

16.00	Michael Caligiuri	AHR: Driving differentiation of human NK cell development (#02)
16.20	Markus Uhrberg	Formation of KIR repertoires: influence by intrinsic and extrinsic factors (#03)
16.40	Thierry Walzer	Liver and bone marrow NK cells correspond to distinct lineages under the control of T-bet and Eomes respectively (#04)
16.52	Matthew Gumbleton	SHIP1 is intrinsically required for NK development and effector function (#05)
17.04	Monika Enqvist	Unique Role for DNAM-1 as a Sensor and Effector Molecule in Human Natural Killer Cell Education (#06)
17.16	Andrew P. Makrigiannis	Licensed natural killer cell significantly increase mouse morbidity and mortality during influenza virus infection (#07)

17.30 – 20.00 Welcome Reception and Dinner

## Thursday, September 19<sup>th</sup>

08.00 – 18.00 Registration

### 09.00 – Session 2 “NK cell education and function” 10.30 Chairs: Petter Höglund, Chiara Romagnani

09.00	David Raulet	The regulation of NK cell responsiveness and self tolerance (#08)
09.20	Katharine Hsu	Is higher education always helpful: lessons from KIR3DL1 and HLA-Bw4 (#09)
09.40	Todd A. Fehniger	microRNA-15/16 antagonizes Myb to regulate NK cell differentiation and maturation (#10)
09.52	Christian Breunig	miRNA involved in immune escape and apoptosis resistance mechanisms in breast cancer (#11)
10.04	Joanna Baginska	Granzyme B degradation by autophagy decreases tumor cell susceptibility to Natural Killer-mediated lysis under hypoxia (#12)
10.16	Monica Killig	Analyzing and modeling the dynamics of differentiating and adoptively transferred NK cells in patients undergoing hematopoietic stem cell transplantation (HSCT) (#13)

10.30 – 11.00 Coffee Break

**11.00 – Session 3 “NK receptors and signaling”**  
**12.30 Chairs: Francesco Colucci, David Margulies**

11.00	Eric Vivier	Regulation of NK cell function (#14)
11.20	André Veillette	Regulation of NK cell activation by SAP family adaptors and SLAM family receptor (#15)
11.40	Roy Mariuzza	Structural basis for genetically linked recognition in the NK gene complex (#16)
12.00	Yvonne Bartel	Genetically coupled receptor-ligand pair NKp80-AICL (#17)
12.12	Richard Berry	Targeting of a natural killer cell receptor family by a viral immunoevasin (#18)

**12.30 – 14.00 Lunch (meet the speakers I)**

**14.00 – Session 4 “NK receptors and signaling”**  
**15.40 Chairs: Veronique Braud, John Coligan**

14.00	Eric Long	Proteomics and imaging to study NK cell signaling (#19)
14.20	Daniel Davis	NK cell biology on the nanometre-scale (#20)
14.40	Jordan Orange	Organizing actin and lytic granules to enable NK cell cytotoxicity and further insights from rare human disease (#21)
15.00	Petra Netter	How a killer gets loose – Analysis of NK cell detachment from tumor cells. (#22)
15.12	Nadia Guerra	NKG2D promotes the development of hepatocellular carcinoma (#23)
15.24	Iliia Voskoboinik	Understanding the mechanism of the cytotoxic granule death pathway (#24)

**15.40 – 18.00 Free time / networking**

**16.00 – Tutorial session “Mathematical modeling”**  
**17.30 Chair: Ramit Mehr**

16.00	Carsten Watzl	Introduction
16.10	Ramit Mehr	Modeling population dynamics and repertoires
16.40	Jayajit Das	Modeling signaling and other molecular processes
17.10		Questions and discussion

**18.00 – 19.30 Dinner**

**19.30 – 21.30 Poster Session 1 (open Bar)**

**Friday, September 20<sup>th</sup>**

**09.00 – Session 5 “NK subsets and memory”**  
**10.30 Chairs: Adelheid Cerwenka, Bill Seaman**

09.00	Lewis Lanier	NK Memory (#25)
09.20	Wayne Yokoyama	Tissue-resident NK cells (#26)
09.40	Joseph C. Sun	Molecular programming of immunological memory in natural killer cells (#27)
09.52	Silke Paust	Natural Killer cell mediated adaptive immunity in trans-nuclear mice and humanized mice (#28)
10.04	Georg Gasteiger	IL-2 dependent adaptive control of NK cell homeostasis and responsiveness (#29)
10.16	Julien Cherfils-Vicini	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells (#30)



**10.30 – 11.00 Coffee Break****11.00 – 12.30 Session 6 “NK cells and viral immunity”  
Chairs: Alexander Steinle, Kalle Malmberg**

11.00	Christian Münz	<b>NK cell responses during human tumorvirus infection (#31)</b>
11.20	Markus Altfeld	<b>NK cell function in HIV-1 infection (#32)</b>
11.40	Hans-Gustaf Ljunggren	<b>NK cell responses to human hantavirus infections (#33)</b>
12.00	Frank Momburg	<b>Immunotherapeutic retargeting of NK and T cells towards HBV-infected target cells using bispecific antibody constructs (#34)</b>
12.12	Edward Barker	<b>NKG2A/CD94, imparts primary natural killer cells with the capacity to be highly cytolytic towards autologous HIV-infected T-cells in the absence of killer immunoglobulin receptors despite HLA-E presences on the infected cell surface (#35)</b>

**12.30 – 14.00 Lunch (meet the speakers II)****14.00 – 15.40 Session 7 “NK cells and cancer”  
Chairs: Daniela Pende, Winfried Wels**

14.00	Laurence Zitvogel	<b>NKp30 isoforms dictate clinical outcome in high risk neuroblastoma (#36)</b>
14.20	Jack Bui	<b>IL-17D and NK cells in tumor rejection (#37)</b>
14.40	Sarah Cooley	<b>Therapeutic Applications of NK Cells (#38)</b>
15.00	Eva Schlecker	<b>Expression and regulation of B7-H6 in tumor cells (#39)</b>
15.12	Katrin S. Reiners	<b>RIG-I stimulation of melanoma cells induces the release of BAG6-positive exosomes, which trigger NK cell activity in vitro and induce a potent anti-tumor response in vivo (#40)</b>
15.24	Joachim Koch	<b>Inhibition of NKG2D-dependent immune escape for improved NK cell therapy of cancer (#41)</b>

**15.40 – 18.00 Free time / networking****16.00 – 17.30 Science Career Session**

Discussion panel with

Ramit Mehr, Katharina Hsu, David Raulet, Petter Hoglund

**18.00 – 19.30 Dinner****19.30 – 21.30 Poster Session 2 (open Bar)****Saturday, September 21<sup>st</sup>****09.00 – 10.30 Session 8 “Innate lymphoid cells and decidual NK cells”  
Chairs: Christian Vosshenrich, Ashley Moffett**

09.00	Hergen Spits	<b>Plasticity of human Innate Lymphoid Cells (#42)</b>
09.20	Andreas Diefenbach	<b>Transcriptional and epigenetic control of innate lymphoid cell lineage specification (#43)</b>
09.40	Marco Colonna	<b>ILC in pathogenic infections (#44)</b>
10.00	Andrew M. Sharkey	<b>Maternal activating receptor KIR2DS1 on decidual NK cells enhances placentation (#45)</b>
10.12	Jens Kieckbusch	<b>Strong inhibition of maternal NK cells by paternal MHC results in compromised reproductive fitness (#46)</b>

**10.30 – 11.00 Coffee Break****11.00 – Session 9 “NK cells and viral immunity”  
12.30 Chairs: Miguel Lopez-Botet, Angel Porgador**

11.00	Stipan Jonjic	Curious case of specific recognition of MCMV by NK cells: the role of uORFs and ncRNAs (#47)
11.20	Mariapia Degli-Eposti	Novel immunoregulatory functions of NK cells (#48)
11.40	Elisabeth Littwitz	Distinct roles of NK cells in viral immunity during different phases of an acute retroviral infection (#49)
11.52	Hugh T. Reyburn	Increased expression of NKG2D ligands after virus infection depends on innate immune recognition of double-stranded RNA (#50)
12.04	Vincent Vieillard	A novel isoform of MLL5 is a cellular ligand for the natural killer cell lysis activating NKp44 receptor (#51)
12.16	Yenan T. Bryceson	Cytomegalovirus drives methylation-dependent epigenetic reprogramming of NK cells (#52)

**12.30 – 14.00 Lunch (meet the speakers III)****14.00 – Session 10 “NK cell function and dysfunction”  
15.30 Chairs: Lutz Walter, Jacques Zimmer**

session sponsor  
Edward P. Evans Foundation

14.00	Sonya Marshall-Gradisnik	Natural Killer cell Function and Gene Expression in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (#53)
14.20	Bibi Bielekova	Regulatory role of CD56bright NK cells in multiple sclerosis revealed by daclizumab therapy (#54)
14.40	Evelyn Ullrich	CD11b+ NK cells are the main effector NK cell subpopulation that impairs GVHD (#55)
14.52	Kerry S. Campbell	NK Cell Dysfunction in Chronic Lymphocytic Leukemia (#56)
15.04	Korbinian Kropp	Platelets impair NK cell immunosurveillance by altering expression and shedding of ligands for the activating immunoreceptor NKG2D from the surface of (metastasizing) tumor cells (#57)
15.16	Salim Khakoo	Hypofunctionality of NK cells following liver transplantation is associated with STAT4 downregulation (#58)

**15.30 – 16.00 Coffee Break****16.00 – Session 11 “NK cells and infection”  
17.30 Chairs: Eleanor Riley, Joachim Koch**

16.00	Ofer Mandelboim	Urinary pathogenic E.coli kill Natural Killer cells to establish urinary tract infection (#59)
16.20	Salomé Leibundgut Landmann	IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells (#60)
16.32	Nikola Baschuk	A cell intrinsic role for Granzyme M: directing inflammation (#61)
16.44	Ray Welsh	Natural killer cell control of adaptive immunity and viral persistence. (#62)
17.04	Alessandro Moretta	NK cells and pathogen infection (#63)
17.24	Closing remarks and invitation to next meeting	

**17.30 – 19.00 Free time / networking****19.00 Gala Dinner (Heidelberg historic castle)**

The 15<sup>th</sup> meeting of the Society for Natural Immunity (NK2015) will be May 2-6, 2015 in Fairmont - Le Chateau Montebello, Montebello, Quebec, Canada.

# List of posters

All posters will be displayed during the entire meeting. Authors of odd numbered abstracts are expected to present their poster in poster session 1 (Thursday, Sept. 19th, 19.30 – 21.30 h). Even numbered posters will be presented in poster session 2 (Friday, Sept. 20th, 19.30 – 21.30 h).

#	presenting author	title
100	Jenny M. Karo	RAG deficiency predisposes a reduced cellular fitness in natural killer cells revealed during viral infection
101	Isabela Pedroza-Pacheco	Cord blood regulatory T cells suppress NK cell differentiation from haematopoietic stem cells
102	Christelle Retière	Large spectrum of HLA-C recognition by KIR2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/2DS2 on KIR2D NK cell repertoire formation
103	Ramit Mehr	NK cell maturation population dynamics: not a simple linear scheme
104	Tomasz Kostrzewski	Post translational modifications of E4BP4 regulate the development of NK cells
105	Spada, Roberto	Organ-specific phenotypic and functional properties of NK cells and NKG2D ligands in murine systemic lupus erythematosus models
106	Patricia Chaves	Loss of canonical Notch signaling affects multiple steps in NK cell development
107	Virginie Renoux	Identification and characterization of human NK lineage restricted progenitor
108	Martin A. Ivarsson	Developmental stages of human fetal NK cells defined by analysis of transcription factors and cell surface proteins using multicolor flow cytometry
109	Laura Chiossone	In vivo generation of decidual NK cells from resident hematopoietic progenitors.
110	C. Neudoerfl	The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs
111	Martin Felices	Survival of the fittest: educated NK cells are more protected from cell death and target other NK cells through Fas/FasL interactions when IL-15 is limiting
112	Takashi Ebihara	Inducible expression of MHC class I licenses NK cells through Ly49 receptor trans-interactions
113	Sadia Salam	Natural Killer cell education and tolerance under conditions of mixed haematopoietic chimaerism.
114	Stephanie Krieg	Phenotypical and functional properties of human thymic NK cell subsets
115	Martin R Goodier	Impact of Age on the function of CD57 defined NK cell subsets
116	Elisabeth Straka	Cell-intrinsic and –extrinsic role of STAT1 in NK cell biology
117	Carmelo LUCI	Modulation of vaginal CD8 T cell responses by natural killer cells
118	E.Hofer	Human NK cells generated ex vivo in the presence of IL12 display more mature phenotypes with improved therapeutic potential
119	Alasdair J. Allan	CATTLE NK CELLS ARE A HIGHLY HETEROLOGOUS POPULATION: IMPLICATIONS FOR DISEASE RESISTANCE
120	Nicole Marquardt	Differentiated KIR+ NK cells are enriched in human adult lung.
121	Elisa Montaldo	Identification of IL-17+RORγt+CD34+ as lineage-specific progenitors of IL-22+NCR+RORγt+ Innate Lymphoid cells
122	Kerstin H. Mair	CD3+NKp46+ lymphocytes with a mixed NK-/T-cell phenotype are present in lymphatic organs in the pig
123	Vivien Béziat	INFLUENCE OF KIR GENE COPY NUMBER ON NATURAL KILLER CELL EDUCATION
124	Amanda Sudworth	A subset of NK cells negative for Ly49s3 and NKR-P1B demonstrate decreased functionality
125	Eileen Auth	Immune reconstitution of NK cell subsets post hematopoietic stem cell transplantation
126	Loris Zamai	In vitro NK cell differentiation from CD34+ hematopoietic progenitors suggest a distinct origin of CD56bright and CD56dim NK cell subsets
127	Sam Sheppard	Characterization of a novel NKG2D and NKp46 double-mutant mouse.
128	Peggy Riese	Highly functional NK cells with enhanced anti-viral activity are stimulated by the NKT cell agonist αGalCerMPEG
129	Arnika K. Wagner	DNAM-1 expression on NK cells correlates with licensing
130	D.A. Lee	NK Cell Deficiency Patients with STAT3 mutations
131	Stina Wickström	Hyporesponsiveness induced by blockade of inhibitory Ly49 receptors in vivo – implications for recognition of tumor vs normal cells.
132	Luis J. Sigal	Severely altered maturation of NK cells in mid-aged mice is due to the aged environment and cannot be reversed by IL-15+IL-15Rα treatment
133	Barbara L. Kee	Analysis of the requirements for ID2 in mature natural killer cells
134	Frank Cichocki	Expansion of highly functional NK cells selectively lacking B and myeloid cell-related proximal signaling molecules upon CMV reactivation in umbilical cord blood transplant recipients.
135	Andrea Ponzetta	Multiple Myeloma growth differently affects Natural Killer cell subset trafficking to bone marrow
136	Al Omar S	No association of HLA-G 14-bp deletion/insertion polymorphism with recurrent spontaneous abortion in Saudi patients
137	Dorothy K. Sojka	Liver-resident NK cells form a distinct lineage from conventional splenic NK cells
138	Janina Kaudeer	A soluble fragment of the NKp30 ligand BAG-6 inhibits NK cell activation
139	Mark S. Gibson	Persistent but limited Ly49 diversity during ruminant evolution

140	Helle Jensen	Molecular requirements for activation of NK cells by the NKG2D receptor
141	John Trowsdale	KIR AND LILR COPY NUMBER VARIATION AND DISEASE
142	Mar Vales-Gomez	GPI-anchored MICA alleles: a biochemical modification with trafficking and functional consequences
143	Andrew P. Makrigiannis	The NKR-P1D:Clr-b recognition system is a negative regulator of innate immune responses in C57BL/6 mice
144	Antoine Marçais	The Akt/mTOR pathway is an essential component of IL-15 signalling during NK cell development and activation.
145	S. López-Cobo	Transfer of ligands for the immune activating receptor NKG2D from target cells to NK cells requires receptor-ligand interaction
146	Angélica Cuapio	CD56bright NK cells modulatory function is enhanced by anti-CD25, IFN $\beta$ -1a and natalizumab in multiple sclerosis
147	Ana Stojanovic	CTLA-4 IS EXPRESSED BY ACTIVATED MOUSE NK CELLS AND INHIBITS NK CELL IFN- $\gamma$ PRODUCTION IN RESPONSE TO MATURE DENDRITIC CELLS
148	Cornelia Fabritius	The functional influence of activating NK cell receptors in solid allograft rejection
149	Maren Claus	Effect of Intravenous Immunoglobulin on the Function of human Natural Killer cells
150	Agnieszka Witalisz	Characterisation of kinase-dependent and -independent role of tyrosine kinase 2 in NK cell biology
151	Andrew Brooks	Diverse contribution of Bw4 residues to ligand recognition by KIR3DL1
152	John E Coligan	Membrane-type 6 Matrix Metalloproteinase, MT6-MMP, Regulates the Activation Induced Down-Modulation of CD16 in Human Primary NK Cells
153	Timor Glatzer	The activating receptor NKp44 elicits inflammatory signatures in ROR $\gamma$ t+ innate lymphoid cells
154	Sara Tognarelli	Human NK cells and autoimmune vasculitis: role of the target cells.
155	Huaijian Guo	Mechanism of inhibition by CRACC, a SLAM family receptor expressed in NK cells
156	Luis-Alberto Pérez-Quintero	EAT-2, a SAP-related adaptor, enhances NK cell activation by stimulating phospholipase C-gamma, calcium fluxes and Erk and by promoting granule polarization towards target cells.
157	ELSA A. MARQUEZ	PEPTIDE DEPENDENT RECOGNITION OF MHCI BY THE NATURAL KILLER CELL RECEPTOR LY49C, IS DRIVEN BY AUXILIARY ANCHOR RESIDUES
158	Michael Brusilovsky	A Genome-Wide siRNA Screen reveals that Heparan Sulfate Proteoglycans can interact with and modulate the function of KIR2DL4
159	Theresa L Geiger	Regulation of virus-specific natural killer cell memory by IL-10 and TGF- $\beta$
160	Ariella Glasner	Ncr1 shapes melanoma structural properties to prevent metastasis
161	Shu Shun Li	NK cell receptor-mediated direct fungal recognition and cytotoxicity that is defective in HIV-infected patients but restored using IL-12
162	Fernando Souza-Fonseca-Guimaraes	Interferon- $\gamma$ and Granulocyte/Monocyte Colony-stimulating Factor Production by Natural Killer Cells Involves Different Signaling Pathways and the Adaptor Stimulator of Interferon Genes (STING).
163	Stephen K Anderson	Characterization of a weakly expressed KIR2DL1 allele
164	Marina Babic Cac	The role of NKG2D in CD4+ T cell functions and lineage commitment
165	Björn Bulitta	Novel kinases involved in NK cell effector responses and microtubule dynamics
166	Marwan Sleiman	TAP-deficient NK cells; a desperate quest for their KIR ligands
167	Heinrich Schlums	EAT2 controls SLAM-family receptor-mediated immunoregulatory NK cell co-activation
168	Marit Inngjerdingen	Combining sub-cellular fractionation, immunoprecipitation, and antibody array analysis for high-throughput analysis of signal transduction in NK cells.
169	Kiva Brennan	Activated NK cells can express NKG2D ligands
170	Elisa Cisneros	Common and recombinant arrangements of the KIR-gene complex in a South European population
171	Maren Claus	Modulation of NK cell function by interactions between 2B4 and CD48 in cis and in trans
172	Julia Herrmann	Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands
173	Jayajit Das	Spatial clustering of inhibitory receptors plays a crucial role in mediating KIR antagonism
174	David H. Margulies	Structural Evolution of NKG2D Ligands and Cytomegalovirus Immuno-evasins
175	Daniel W McVicar	Molecular Dissection of the Function of KIR3DL1 allotypes: Implications for HLA-Bw4 80I/80T discrimination and variable HIV peptide recognition.
176	Sumi Rajagopalan	TLR-like properties of KIR2DL4: NF- $\kappa$ B activation through TRAF6 and TAK1
177	Angela Manser	Analysis of KIR repertoires on human T cells reveals selective expression of KIR3DL2 on a subset of naïve CD4 T cells
178	Markus Granzin	Extensive Characterization of Ex Vivo Activated and Expanded Human NK Cells for Cancer Therapy
179	Van Acker Aline	The role of Ly49E receptor expression on intestinal intraepithelial lymphocytes in inflammatory bowel diseases
180	Jessica Filtjens	Abundant stage-dependent Ly49E expression by liver NK cells is not essential for their differentiation and function
181	Linda Quatrini	MICA and ULBP2-induced NKG2D down-modulation is differentially regulated: contribution of the ubiquitin ligase c-Cbl.
182	Cristina Capuano	CD16 aggregation induced by therapeutic antibody-opsonised targets impairs cytotoxic responses in human NK cells
183	Buccella Flavia	Evaluation of the degranulation process induced by NKp46 stimulation in different NK cell subsets

184	Sorcha Cassidy	Low affinity peptide sensitivity of KIR2DL2 and KIR2DL3 homozygous donors
185	EnJun Yang	Augmentation of diacylglycerol signaling enhances NK cell function without affecting Ly49 receptor acquisition by NK cells during development
186	Dongfang Liu	An essential role of adaptor protein CrkL in NK cell cytotoxicity
187	Gulnur K. Zakiryanova	C-kit positive human peripheral blood NK cells express Stem cell factor
188	Olympe Chazara	Immunogenetics of killer cell immunoglobulin-like receptors (KIR) and HLA-C in pregnancy
189	Casimir de Rahm	Immunogenicity of human pluripotent stem cells and their derivatives: focus on natural killer cells
190	Ashley Moffett	Maternal KIR and fetal HLA-C genes determine the risk of pre-eclampsia in Uganda
191	Alexandra Vrazo	Development of a high throughput screening assay to identify genetic modifiers of NK cytotoxicity
192	Kathrin Schönberg	The influence of ruxolitinib, a JAK1/2 inhibitor, on NK cell function and proliferation
193	Merlin Luetke-Eversloh	Memory-like and terminally differentiated NK cells undergo epigenetic remodeling of the IFNG locus
194	Hun Sik Kim	Natural Killer Cells from Patients with Chronic Rhinosinusitis Have Impaired Effector Functions
195	Moustapha Mbow	Natural Killer cells of HIV-1 exposed but uninfected subjects exhibit recall responsiveness to HIV-1 peptides
196	D.M. Tufa	Human Six-Sulfo LacNAc DCs enhance activation and function of Natural Killer Cells: the role of cell surface and soluble molecules
197	Rebecca Riise	Neutrophilic priming of NK cells enhance the response to ensuing IL-12 stimulation
198	Carolyn M Nielsen	Vaccine induced activation of natural killer cells is restricted to the CD57- subset
199	Volker Huppert	New technology for fast isolation of NK cells from human whole blood
200	Maxi Scheiter	S100A4 is a novel component of the NKIS coordinating NK cell cytotoxicity
201	Martin Prlic	Inflammation drives memory CD8 T cells to temporarily become NK-like effectors
202	Christian Markus Hüber	Fate mapping long-lived NK cells
203	Matthias Miller	TOWARDS THE DEVELOPMENT OF NEXT-GENERATION NK CELL THERAPY: CHARACTERIZATION OF IL-12/15/18 PREACTIVATED NK CELLS FOR TUMOR THERAPY
204	Konrad Krzewski	NK cell function in the lysosomal storage disorder, Chediak-Higashi syndrome.
205	Jing Ni	Long-term persistence of cytokine-induced NK cell function requires CD4+ T cell help
206	Nathalie Jacobs	Novel cooperation between CX3CL1 and CCL26 inducing NK cell chemotaxis via CX3CR1: a possible mechanism for NK cell infiltration of the allergic nasal tissue
207	Rehab Alnabhan	A Study of Peripheral Blood and Cord Blood Natural Killer Cell Activation
208	Paola Carrillo-Bustamante	Viral driven evolution of KIR complexity
209	D. Chatterjee	The role of notch and activin-A in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell effector functions
210	Elin Forslund	NK cell interaction with micropatterned immune synapses: spatial distribution and ligand regulate contact time, migration and morphology.
211	Srividya Sundararaman	Fluorescence-Imaging Based Detection of Natural Killer Function via Cytotoxicity Assays
212	Sandeep K. Tripathy	Viral infection transiently reverses activation receptor mediated NK cell hyporesponsiveness in an MHC class I independent manner
213	Jürgen Schmitz	Virus antigen specific cytotoxicity of human NK cells
214	Karolin Guldevall	Investigation of Serial Killers – A Screening Approach for Characterization of Single NK cells isolated in microwell arrays.
215	Catharina C. Gross	Defective Immune Regulatory Function of NK Cells in Multiple Sclerosis (MS)
216	Martha-Lena Mueller	A N-terminal missense mutation in STX11 causative of FHL4 abrogates syntaxin-11 binding to Munc18-2
217	Guanqiao Li	NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity
218	Emily M. Mace	Super-resolution nanoscopy reveals a role for F-actin disassembly in lytic granule conduit formation, but not MTOC docking, at the NK cell lytic immune synapse
219	E. Marion Schneider	Ultrastructural characteristics of in vivo activated NK cells killing autologous and allogeneic inflammatory dendritic cells.
220	Asia-Sophia Wolf	NK cell phenotype defines the balance of functional responses in malaria responders
221	D.A. Lee	Single-cell analysis reveals functional consequences of high-affinity FcR ligation in NK cells by Fc-modified antibodies.
222	Sharline Madera	IL-18-MyD88 signaling axis is important in the attainment of a robust virus-specific effector NK cell response but dispensable for memory formation
223	Jörg D. Seebach	REDUCTION OF HUMAN NK CELL RECRUITMENT BY HLA-E EXPRESSION ON PORCINE ENDOTHELIUM IN AN EX VIVO XENOGENEIC PIG-LEG PERFUSION MODEL
224	Rachel J. Bergerson	Early NK Proliferation After Allogeneic Hematopoietic Cell Transplantation Is Associated With Superior Disease Free Survival Due To Reduced Leukemia Relapse

225	Aimee Beaulieu	The transcription factor Zbtb32 controls the proliferative burst of virus-specific NK cells responding to infection
226	Sunitha Bagawath Singh	Role of cis interaction between Ly49A receptor and MHC class I molecule for NK cell function
227	Jörg D. Seebach	DECREASED NUMBERS AND FUNCTION OF PERIPHERAL BLOOD NATURAL KILLER CELLS IN END-STAGE LIVER DISEASE
228	Elena I Kovalenko	LIPOPOLYSACCHARIDE MODULATES NK CELL ACTIVITY
229	Nathalie Jacobs	Expansion of CD16+ CD56+ NK cells in vericyte® NK cell growth medium.
230	Athanasia E. Christakou	Live Cell Imaging in a Micro-Array of Acoustic Traps Facilitate Quantification of Natural Killer Cell Heterogeneity and Solid Tumor Spheroid Formation
231	Vanda Juranic Lisnic	Complex MCMV regulation of PVR to avoid NK cell recognition
232	Karin Tennert	HSV-1-infected monocytes are crucial in natural killer cell activation via production of TNF-alpha
233	Anna Lünemann	HUMAN HEPATIC CXCR6+ NK CELLS ACCUMULATE UPON HIV INFECTION IN MICE RECONSTITUTED WITH HUMAN IMMUNE SYSTEM COMPONENTS
234	Kerstin A Stegmann	IL-2R $\alpha$ (CD25) receptor expression on murine NK cells during malaria infection
235	Cormac Cosgrove	HBV and HCV infection drive distinct immunophenotypic and functional NK cell profiles in the acute phase of infection
236	William T. Nash	Ly49G2+ NK cells regulate the balance of inflammation and dendritic cells following MCMV infection
237	Zachary Davis	Natural killer cell destruction of autologous HIV-1 infected primary T-cell blasts involves DNAM-1 recognition of CD155 on infected cells.
238	L.Fainboim*	Functional KIR2DS4 Allele Found Increased in Chronically Infected HCV Patients is Associated with its Expression on NK and Highly Differentiated CD8+ Cells
239	Benjamin Vogel	Efficient Generation of Human Natural Killer Cell Lines by Viral Transformation
240	Vincent Vieillard	NKp44L expression on CD4+ T Cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy
241	Leslie A. Fogel	The role of apoptosis in the termination of NK cell activation.
242	Manuela Moraru	A combination of CD16A and IgG1 allotypes protects from clinical HSV-1 infection
243	Joshua D. Brandstadter	IL-18 Signaling on Dendritic Cells Is Required for Efficient NK Cell Activation to Vaccinia Virus
244	M.I. Garcia-Laorden	Role of granzyme A and B in pneumonia caused by Klebsiella pneumoniae
245	Leonie Dengler	Depletion of NK cells lead to opposed phenotypes in mice after influenza A infection
246	Gundula Min-Oo	Specificity of MCMV-induced memory NK cells: impaired response to challenge with heterologous infections in vivo
247	Monika Braun	Hantaviruses employ multiple mechanisms to evade NK cell recognition
248	Zequang Wu	Natural Killer cells control Human Cytomegalovirus transmission: Innate and Adaptive immunity dependent mechanisms
249	Aura Muntasell	NKG2C Zygosity Influences CD94/NKG2C Receptor Function and the NK-cell Compartment Redistribution in Response to Human Cytomegalovirus
250	Jerome D Coudert	NK cells fight off an MCMV strain that targets inhibitory receptors by cis-masking.
251	Kathrin Gibbert	Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection
252	Stephen N. Waggoner	The traitors within: how vaccine development may be undermined by natural killer cell restriction of humoral and cellular immune memory
253	Sandra López-Vergès	CD56negCD16+ NK cells result are mature NK cells with impaired function during HIV-1 infection
254	Zakia Djaoud	Amplified NKG2C+ NK cells in CMV infection preferentially express KIR2DL: functional impact in controlling CMV-infected dendritic cells
255	Sebastian Lunemann	Dynamics of NK cell responses to hepatitis delta virus infection during the course of IFN $\alpha$ -treatment
256	Jeffrey J. Teoh	Selective regulation of co-stimulatory ligand display by Ly49G2+ NK cells is needed to enhance short-lived CD8+ T cell effector response to MCMV
257	Tolga Sutlu	Enhancing lentivirus-mediated gene delivery to natural killer cells
258	Tihana Trsan	RAE-1 $\gamma$ ligand expression by MCMV vector promotes induction and maintenance of protective immune memory
259	Seung-Hwan Lee	EFFECT OF STAT6 ON ANTI-VIRAL IMMUNE RESPONSES
260	Mala K Maini	NKG2D-dependent T cell/NK cell interactions in a hepatotropic viral infection
261	Jamie L. Schafer	Modulation of KIR-Mediated NK Cell Inhibition by Simian Immunodeficiency Virus Peptides
262	Amanda J. Lee	Type I interferon signalling indirectly activates natural killer cell interferon- $\gamma$ production during vaginal HSV-2 infection
263	A. Boonstra	Prospective monitoring of liver NK cells of chronic HBV patients, and modulation by viral load reduction during antiviral therapy
264	Doris Urlaub	A novel secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates NK cell functions
265	Dominique Knoll	NK Cell Response in Visceral Leishmaniasis is Dependent on Neutrophils

266	Luis J. Sigal	Pas de trois: entry of protective NK cells to the lymph node draining the site of ectromelia virus infection requires the coordinated action of TLR9/MyD88-expressing Migratory Dendritic Cells and CXCL9-producing inflammatory monocytes
267	Julia Hengst	NK cell frequency and phenotype affect the outcome of acute hepatitis virus C infection
268	Christian Körner	Expansion and increased polyfunctionality of KIR2DL1+ NK cells in individuals with primary HIV-1 infection is associated with carriage of the cognate HLA-C group 2 ligand haplotype
269	Sytse J. Piersma	Dual cytokine and activation receptor signaling is required for optimal NK-cell responses during initial MCMV infection
270	Chelsea L Davidson	INVESTIGATING LEUKOCYTE IG-LIKE RECEPTOR 1 (LIR-1) GENOTYPE AND SUSCEPTIBILITY TO CMV DISEASE
271	Cáit Ní Chorcóra	Differential binding of HLA-A*03 restricted HCV derived peptides to KIR3DL2 and LILRB1 receptors
272	ramakrishna vankayalapati	Role of NK cells in Mycobacterium tuberculosis infection
273	Tarik Azzi	Early-differentiated natural killer cells expand during infectious mononucleosis and preferentially target lytic EBV replication
274	Clive M Michelo	KIR and HLA associated genotypic risk of Cytomegalovirus (CMV) infection and disease in renal transplantation
275	Biljana Zafirova	Selective expression of type I IFNs by plasmacytoid DCs activates NK cells and is sufficient to control MCMV infection
276	Stephanie Jost	Therapeutic Vaccination using HIV-1 gp120/NefTat/AS02A enhances responsiveness of NK Cells through the induction of gp120-specific CD4+ T Cell Help
277	Helena Meßlinger	In vitro interaction of human NK cells with Leishmania parasites
278	Yotam Bar-On	Neuraminidase-mediated, NKp46-dependent immune evasion mechanism of influenza viruses
279	Casimir de Rham	The Role of the KIR Receptors Expressed by Natural Killer Cells During Acute CMV Infection After Kidney Transplantation
280	Idan Milo	In vivo imaging reveals the BM as depot for mature proliferating NK cells
281	Jacki Kornbluth	NATURAL KILLER LYTIC-ASSOCIATED MOLECULE PLAYS A ROLE IN CONTROLLING THE MATURATION AND IMMUNOPHENOTYPE OF MYC-INDUCED B CELL LYMPHOMAS
282	Bin Qu	A real-time cytotoxicity assay to analyze killer cell function and for personalized immunotherapy
283	Julia Wild	The TNF-family member BAFF is released by NK cells which enables evasion of Chronic Lymphoid Leukemia cells from direct and Rituximab-induced NK cell reactivity
284	Jens HW Pahl	Induction of anti-tumor activity of human macrophages against osteosarcoma cells
285	Evelien E Bouwmans	NK cells expanded with the ZRP cultivation system keep cytotoxic properties and remain alloreactive
286	Scot D Liu	Afucosylated antibodies increase activation of FcγRIIIA-dependent signaling components and intensifies cytotoxic processes promoting NK cell-mediated ADCC
287	Matthias Pfeiffer	Simultaneous expansion and activation of NK- and gamma-delta T cells for immunotherapy
288	G.H. Boerman	Trastuzumab and Cetuximab promote cytotoxicity of resting Natural Killer cells towards Rhabdomyosarcoma in vitro
289	Grzegorz Terszowski	NEGATIVE IMPACT OF KIR/HLA INTERACTIONS ON NK CELL ACTIVITY CAN BE OVERCOME BY THE GLYCOENGINEERED ANTIBODY GA101 (Obinutuzumab)
290	Anne Caignard	NK cells infiltrating regional metastatic Lymph Nodes from stage III melanoma patients: a new population of CD56bright CD16+ NK cells
291	Fauriat C.	Reconstitution of Natural Killer Cells In HLA-Matched Stem Cell Transplantation With Peripheral Stem Cells After Reduced Intensity Conditioning
292	Zena Khaznadar	Acute Myeloid Leukemia cells evade from NK cells by forming an impaired immunological synapse
293	Florian Babor	Characterization of leukemia-specific NK cell subsets against acute lymphoblastic leukemia in children
294	Ardolino, M.	NK cells infiltrating MHC-deficient tumors are tuned to a hypo-responsive state that can be reverted by a pro-inflammatory environment.
295	Joanna Kritikos*	WASp regulates NK cell killing of tumor cells
296	Andreas Lundqvist	Prostaglandin E2 induces myeloid-derived suppressor cells that impair natural killer cell activity through production of TGFβ
297	Sang-Ki Kim	Effect of IL-21 on the proliferation and cytotoxic activity of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells
298	Hans Klingemann	Targeted Anti-Tumor Activity with the Natural Killer Cell Line NK-92
299	Dhifaf Sarhan	STAT3 phosphorylation status in dendritic cells plays a critical role in the outcome of NK cell activity
300	Jean-Marc Doisne	Suppression of selective lymphocyte functions by p110δ inactivation improves the outcome of allogeneic hematopoietic cell transplantation.
301	Bernadett J. Mueller	NK cells are decreased in Hepatocellular carcinoma despite high levels of recruiting chemokines
302	Katia GAGNE	Impact of cord blood inhibitory KIR+ NK cell alloreactivity on double umbilical cord blood engraftment
303	Fernando Guimarães	Up-regulation of DNAM-1 and NKp30, associated with improved activation of NK cells after long-term culture of mononuclear cells from patients with ovarian neoplasia

304	Andrew P. Makrigiannis	Ly49 family receptor expression is required for cancer immunosurveillance mediated by natural killer cells
305	Juergen Kuball	Towards clinical $\gamma\delta$ TCR gene therapy: the optimal $\gamma\delta$ TCR T cell product
306	Stefanie Raab	Induction of NK cell response against breast cancer by Fc-modified NKG2D-Ig fusion proteins
307	Pranav Oberoi	Natural Killer Cells Modified to Express a Targeted Granzyme B Fusion Protein for Enhanced Antitumoral Activity
308	Bléry, M.	Pre-clinical characterization of cytotoxic chimeric anti-MICA mAbs candidates for therapeutical indications
309	Sandra Weil	Investigation of tumor immune escape from NKG2D-dependent NK cell cytotoxicity
310	E. M. García-Cuesta	Characterization of bladder cancer cells as target for NK cells during BCG treatment
311	Janine Jahn	Decreased NK cell functions in obesity can be re-activated by weight loss
312	Sabrina Genßler	Genetically Modified Natural Killer Cells Targeting EGFR Expressing Malignancies
313	Congcong Zhang	ErbB2/HER2-specific natural killer cells for adoptive cancer immunotherapy
314	Samuel Körner	Generation and preclinical characterization of an Fc-optimized CD133 antibody for improved induction of NK cell reactivity against myeloid leukemia
315	Boudreau, JE	Development of a multiplex PCR assay to detect functional subgroups of KIR3DL1 alleles
316	Lisa Liu	Selective Expansion of Educated NK cells for Cancer Therapy
317	Biancamaria Ricci	DDR and redox signaling regulates E2F1-dependent expression of ligands for NKG2D and DNAM-1 NK cell activating receptors on drug-induced senescent Multiple Myeloma cells.
318	Tan, T	Melanoma cells that acquire resistance to a BRAF inhibitor can also become resistant to NK cell cytotoxicity.
319	Veronique Braud	Expression of Lectin-Like Transcript 1, the ligand of NKRP-1A receptor on germinal centre-derived B-cell Non Hodgkin's lymphomas
320	Erica B Wilson	Modeling tumour mediated NK cell inhibition in the human tumour microenvironment
321	Erik Ames	NK cells mediate preferential killing of cancer stem cells in solid tissue tumors
322	Cinzia Fionda	Interplay between Glycogen Synthase Kinase-3 and STAT3 in the regulation of NKG2D Ligand MICA expression in Multiple Myeloma cells.
323	U. Siegler	Cellular immunotherapy of hematopoietic malignancies with multiple infusions of good manufacturing practice expanded human natural killer cells
324	Maike Sauer	The NKG2D/NKG2D ligand system as immune sensor for damaged cells: Molecular mechanisms directing the stress-induced expression NKG2D ligands
325	Hiroshi TERUNUMA	Boosting NK cells and $\gamma\delta$ T cells in 138 cancer patients by injecting ex vivo expanded cells
326	Guanqiao Li	NK Cell HMGB1 Modulates NK Functionality And Limits Tumor Growth
327	Giovanni F. Torelli	RECOGNITION OF ACUTE LYMPHOBLASTIC LEUKEMIA BY EXPANDED NATURAL KILLER CELLS
328	Laura F. Wetherill	Rapid and transient NK cell activation in patients treated with Reolysin®
329	Uwe Reusch	A novel tetravalent bispecific CD30/CD16A TandAb efficiently recruits NK cells for the lysis of CD30+ tumor cells
330	Ralf Dressel	Effects of the MICA-129 polymorphism on NK cell function and association with the outcome of hematopoietic stem cell transplantation
331	Hejazi M	Phenotypic and functional NK cell deficiencies in patients with Myelodysplastic Syndrome
332	T. Bobrzynski	NK cell subsets in peripheral blood and carcinoma tissues defined by NKG2A and NKGC expression
333	Ennio Carbone	Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients.
334	Elke Pogge von Strandmann	The CD30 / CD16A bispecific antibody TandAb AFM13 activates NK cells from Hodgkin lymphoma patients resulting in specific tumor cell killing
335	DA Lee	HYPOXIA SIGNIFICANTLY DIMINISHES IL21-INDUCED EX-VIVO EXPANSION OF NATURAL KILLER CELL WITHOUT COMPROMISING NK CELL CYTOTOXICITY
336	Joana C Guedes	NKG2D receptor promotes tumour growth in DEN-induced hepatocellular carcinoma
337	DA Lee	Optimal cryopreservation conditions to preserve viability, proliferation, and lytic function of expanded human NK cells for clinical trials
338	SO Ciurea	GvHD prophylaxis with post-transplant cyclophosphamide for haploidentical stem cell transplantation results in rapid numeric recovery and delayed functional reconstitution of NK cells post-transplant.

# Participant Index

## **Regina Alex**

Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
[reginaa@miltenyibiotec.de](mailto:reginaa@miltenyibiotec.de)

## **Evren Alici**

Karolinska Institute  
Stockholm Sweden  
[evren.alici@ki.se](mailto:evren.alici@ki.se)

## **Alasdair Allan**

The Pirbright Institute  
Woking United Kingdom  
[alsadair.allan@pirbright.ac.uk](mailto:alsadair.allan@pirbright.ac.uk)

## **Rehab Alnabhan**

Anthony Nolan Research Institute  
London United Kingdom  
[rehab.alnabhan.10@ucl.ac.uk](mailto:rehab.alnabhan.10@ucl.ac.uk)

## **Sulimam Alomar**

King Saud University  
Riyadh Saudi Arabia  
[syalomar@ksu.edu.sa](mailto:syalomar@ksu.edu.sa)

## **Marcus Altfeld**

Massachusetts General Hospital  
Cambridge USA  
[maltfeld@partners.org](mailto:maltfeld@partners.org)

## **Erik Ames**

UC Davis School of Medicine  
Sacramento USA  
[eames@ucdavis.edu](mailto:eames@ucdavis.edu)

## **Nadia Anceriz**

Innate Pharma  
Marseille France  
[nadia.anceriz@innate-pharma.fr](mailto:nadia.anceriz@innate-pharma.fr)

## **Stephen Anderson**

National Cancer Institute  
Frederick USA  
[andersonst@mail.nih.gov](mailto:andersonst@mail.nih.gov)

## **Pascale André**

Innate Pharma  
Marseille France  
[pascale.andre@innate-pharma.fr](mailto:pascale.andre@innate-pharma.fr)

## **Michele Ardolino**

University of California, Berkeley  
Berkeley USA  
[michele.ardolino@berkeley.edu](mailto:michele.ardolino@berkeley.edu)

## **Volker Arps**

Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
[volkera@miltenyibiotec.de](mailto:volkera@miltenyibiotec.de)

## **Susanne Arthold**

UCL Cancer Institute  
London United Kingdom  
[s.arthold@ucl.ac.uk](mailto:s.arthold@ucl.ac.uk)

## **Eileen Auth**

University Medical Center Frankfurt  
Frankfurt Germany  
[eileen.auth@kgu.de](mailto:eileen.auth@kgu.de)

## **Tarik Azzi**

University Children's Hospital of Zürich  
Zurich Switzerland  
[tarik.azzi@kispi.uzh.ch](mailto:tarik.azzi@kispi.uzh.ch)

## **Marina Babic Cac**

German Rheumatism Research Centre  
Berlin Germany  
[marina.babic\\_cac@drfz.de](mailto:marina.babic_cac@drfz.de)

## **Florian Babor**

University Medical Center Düsseldorf  
Düsseldorf Germany  
[florian.babor@med.uni-duesseldorf.de](mailto:florian.babor@med.uni-duesseldorf.de)

## **Sunitha Bagawath Singh**

Karolinska Institute  
Stockholm Sweden  
[sunitha.bagawath.singh@ki.se](mailto:sunitha.bagawath.singh@ki.se)

## **Joanna Baginska**

Centre de Recherche Public de la Santé  
(CRP-Santé)  
Luxembourg Luxembourg  
[joanna.baginska@crp-sante.lu](mailto:joanna.baginska@crp-sante.lu)

## **Kanchan Bala**

Institute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
[kg\\_iitd@yahoo.co.in](mailto:kg_iitd@yahoo.co.in)

## **Eva Bär**

ETH Zürich  
Zürich Switzerland  
[eva.baer@micro.biol.ethz.ch](mailto:eva.baer@micro.biol.ethz.ch)

## **Yotam Bar-On**

Hebrew University  
Jerusalem Israel  
[yotam.bar-on@mail.huji.ac.il](mailto:yotam.bar-on@mail.huji.ac.il)

## **Isabel Barao-Silvestre**

University of Nevada, Reno  
Reno USA  
[isilvestre@medicine.nevada.edu](mailto:isilvestre@medicine.nevada.edu)

## **Edward Barker**

Rush University Medical Center  
Chicago USA  
[edward\\_barker@rush.edu](mailto:edward_barker@rush.edu)

## **Yvonne Bartel**

University of Frankfurt  
Frankfurt am Main Germany  
[yvonne.bartel@kgu.de](mailto:yvonne.bartel@kgu.de)

## **Nikola Baschuk**

The Peter MacCallum Cancer Institute  
Melbourne Australia  
[nikola.baschuk@petermac.org](mailto:nikola.baschuk@petermac.org)

## **Aimee Beaulieu**

Memorial Sloan-Kettering  
New York USA  
[beaulieuaimée@gmail.com](mailto:beaulieuaimée@gmail.com)

## **Rachel Bergerson**

University of Minnesota  
Minneapolis USA  
[rjberg@umn.edu](mailto:rjberg@umn.edu)

## **Elin Bernson**

University of Gothenburg  
Gothenburg Sweden  
[elin.bernson@gmail.com](mailto:elin.bernson@gmail.com)

## **Richard Berry**

Monash University  
Clayton Australia  
[richard.berry@monash.edu](mailto:richard.berry@monash.edu)

## **Vivien Béziat**

Karolinska Institute  
Stockholm Sweden  
[vivien.beziat@ki.se](mailto:vivien.beziat@ki.se)

## **Bibiana Bielekova**

National Institutes of Health  
Bethesda USA  
[bielekovab@ninds.nih.gov](mailto:bielekovab@ninds.nih.gov)

## **Andreas Björklund**

Karolinska Institute  
Stockholm Sweden  
[andreas.bjorklund@ki.se](mailto:andreas.bjorklund@ki.se)

## **Niklas Björkström**

Karolinska Institutet  
Stockholm Sweden  
[niklas.bjorkstrom@ki.se](mailto:niklas.bjorkstrom@ki.se)

## **Mathieu Blery**

Innate Pharma  
Marseille France  
[mathieu.blery@innate-pharma.fr](mailto:mathieu.blery@innate-pharma.fr)

## **Jeroen Blokhuis**

Stanford University  
Stanford USA  
[blokhuis@stanford.edu](mailto:blokhuis@stanford.edu)

## **Harmke Boerman**

Leiden University Medical Centre  
Leiden Netherlands  
[g.h.boerman@lumc.nl](mailto:g.h.boerman@lumc.nl)

## **Andre Boonstra**

Erasmus Medical Center  
Rotterdam Netherlands  
[p.a.boonstra@erasmusmc.nl](mailto:p.a.boonstra@erasmusmc.nl)

## **Jeanette Boudreau**

Memorial Sloan-Kettering Cancer Center  
New York USA  
[boudreaj@mskcc.org](mailto:boudreaj@mskcc.org)

## **Selma Boulenouar**

University of Cambridge  
Cambridge United Kingdom  
[sb831@cam.ac.uk](mailto:sb831@cam.ac.uk)

## **Evelien Bouwmans**

University of Maastricht  
Maastricht Netherlands  
[evelien.bouwmans@maastrichtuniversity.nl](mailto:evelien.bouwmans@maastrichtuniversity.nl)

## **Joshua Brandstadter**

Duke University  
Durham USA  
[joshua.brandstadter@duke.edu](mailto:joshua.brandstadter@duke.edu)

**Veronique Braud**  
CNRS UMR7275  
Valbonne France  
*braud@ipmc.cnrs.fr*

**Monika Braun**  
Karolinska Institute  
Stockholm Sweden  
*monika.braun@ki.se*

**Kiva Brennan**  
Trinity College Dublin  
Dublin Ireland  
*kbrenna@tcd.ie*

**Ekua Brenu**  
Griffith University  
Gold Coast Australia  
*e.brenu@griffith.edu.au*

**Andrew Brooks**  
University of Melbourne  
Melbourne Australia  
*agbrooks@unimelb.edu.au*

**Michael Brusilovsky**  
Ben-Gurion University in the Negev  
Beer-Sheva Israel  
*brusmich@post.bgu.ac.il*

**Yenan Bryceson**  
Karolinska Institute  
Stockholm Sweden  
*yanan.bryceson@ki.se*

**Flavia Buccella**  
University of Urbino "Carlo Bo"  
Urbino Italy  
*flavia.buccella@uniurb.it*

**Jack Bui**  
University of California, San Diego  
La Jolla USA  
*jbui@ucsd.edu*

**Björn Bulitta**  
Helmholtz Centre for Infection Research  
Braunschweig Germany  
*bjoern.bulitta@helmholtz-hzi.de*

**Debby Burshtyn**  
University of Alberta  
Edmonton Canada  
*burshtyn@ualberta.ca*

**Anne Caignard**  
INSERMU1016  
Paris France  
*anne.caignard@inserm.fr*

**Michael Caligiuri**  
The Ohio State University James Cancer  
Hospital  
Columbus USA  
*michael.caligiuri@osumc.edu*

**Kerry Campbell**  
Fox Chase Cancer Center  
Philadelphia USA  
*kerry.campbell@fccc.edu*

**Cristina Capuano**  
Sapienza University of Rome  
Rome Italy  
*cristina.capuano@uniroma1.it*

**Ennio Carbone**  
University Magna Graecia of Catanzaro  
Catanzaro Italy  
*ennio.carbone@ki.se*

**Paola Carrillo-Bustamante**  
Utrecht University  
Utrecht Netherlands  
*p.carrillobustamante@uu.nl*

**Adelheid Cerwenka**  
German Cancer Research Center  
Heidelberg Germany  
*a.cerwenka@dkfz.de*

**Debanjana Chatterjee**  
Hannover Medical School  
Hannover Germany  
*chatterjee.debanjana@mh-hannover.de*

**Patricia Chaves Guerrero**  
Lund University  
Lund Sweden  
*patricia.chaves\_guerrero@med.lu.se*

**Olympe Chazara**  
University of Cambridge  
Cambridge United Kingdom  
*oc248@cam.ac.uk*

**Julien Cherfils-Vicini**  
IRCAN (INSER U1081 CNRS 7284)  
Nice France  
*julien.cherfils@unice.fr*

**Laura Chiossone**  
G.Gaslini Institute  
Genoa Italy  
*laurachiossone@hotmail.com*

**Duck Cho**  
Chonnam National University Medical  
School  
Jeollanam-do South Korea  
*dcho@chonnam.ac.kr*

**Athanasia Christakou**  
Royal Institute of Technology (KTH)  
Stockholm Sweden  
*athachris@kth.se*

**Michael Chrobok**  
Karolinska Institute  
Stockholm Sweden  
*michael.chrobok@ki.se*

**Frank Cichocki**  
University of Minnesota  
Minneapolis USA  
*cich0040@umn.edu*

**Elisa Cisneros Leralta**  
Hospital Universitario Puerta De Hierro-  
Majadahonda  
Madrid Spain  
*elicis00@hotmail.com*

**Stefan Ciurea**  
The University of Texas MD Anderson  
Cancer Center  
Houston, TX United States of America  
*sciurea@mdanderson.org*

**Maren Claus**  
IfADo  
Dortmund Germany  
*claus@ifado.de*

**John Coligan**  
NIAID  
Rockville USA  
*jcoligan@niaid.nih.gov*

**Marco Colonna**  
Washington University School of Medicine  
St. Louis USA  
*colonna@wustl.edu*

**Francesco Colucci**  
University of Cambridge  
Cambridge United Kingdom  
*fc287@medschl.cam.ac.uk*

**Graham Cook**  
University of Leeds  
Leeds United Kingdom  
*g.p.cook@leeds.ac.uk*

**Sarah Cooley**  
University of Minnesota  
Minneapolis USA  
*cool0023@umn.edu*

**Markus Cornberg**  
Hannover Medical School  
Hannover Germany  
*cornberg.markus@mh-hannover.de*

**Margareta Correia**  
German Cancer Research Center  
Heidelberg Germany  
*m.correia@dkfz.de*

**Cormac Cosgrove**  
Massachusetts General Hospital  
Cambridge USA  
*pcosgrove@partners.org*

**Jerome Coudert**  
Lions Eye Institute  
Perth Australia  
*jerome@lei.org.au*

**Joana Coutinho Guedes**  
Imperial College London  
London United Kingdom  
*j.guedes12@imperial.ac.uk*

**Steven Cox**  
Anthony Nolan Research Institute  
London United Kingdom  
*steven.cox@anthonyolan.org.uk*

**Angelica Cuapio Gomez**  
Medical University Vienna  
Vienna Austria  
*angelica.cuapiogomez@meduniwien.ac.at*

**Karol Czaja**

University Medical Center Basel  
Basel Switzerland  
*karol.czaja@unibas.ch*

**Jayajit Das**

The Research Institute at the Nationwide  
Childrens Hospital  
Columbus USA  
*das.70@osu.edu*

**Chelsea Davidson**

University of Alberta  
Edmonton Canada  
*chelsead@ualberta.ca*

**Daniel Davis**

University of Manchester  
Manchester United Kingdom  
*daniel.davis@manchester.ac.uk*

**Zachary Davis**

Rush University Medical Center/  
University of Minnesota  
Chicago USA  
*zbdavis@gmail.com*

**Rik de Groen**

Erasmus MC  
Rotterdam Netherlands  
*r.degroen@erasmusmc.nl*

**Casimir de Rham**

University Hospital Geneva  
Geneva Switzerland  
*casimir.derham@hcuge.ch*

**Mariapia Degli-Esposti**

Lions Eye Institute and The University of  
Western Australia  
Perth Australia  
*mariapia@lei.org.au*

**Anibal Delgado Masso**

Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*iq.anibaldm@gmail.com*

**Maria Delso Vallejo**

Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
*mariade@miltenyibiotec.de*

**Leonie Dengler**

Helmholtz Centre for Infection Research  
Braunschweig Germany  
*leonie.dengler@helmholtz-hzi.de*

**Andreas Diefenbach**

University of Freiburg  
Freiburg Germany  
*andreas.diefenbach@uniklinik-freiburg.de*

**Erik Dissen**

University of Oslo  
Oslo Norway  
*erik.dissen@medisin.uio.no*

**Zakia Djaoud**

Etablissement Français du Sang  
Nantes France  
*zakia.djaoud@efs.sante.fr*

**Jean-Marc Doisne**

University of Cambridge  
Cambridge United Kingdom  
*jmd83@medschl.cam.ac.uk*

**Zhongjun Dong**

Tsinghua University  
Beijing China  
*dongzj@biomed.tsinghua.edu.cn*

**Ralf Dressel**

University Medical Center Göttingen  
Göttingen Germany  
*rdresse@gwdg.de*

**Nicolas Dulphy**

Institut Universitaire d'Hematologie  
Paris France  
*nicolas.dulphy@univ-paris-diderot.fr*

**Adil Doganay Duru**

Karolinska Institute  
Huddinge Sweden  
*adil.duru@ki.se*

**Takashi Ebihara**

Washington University School of Medicine  
St. Louis USA  
*tebihara@dom.wustl.edu*

**Susanne Ebner**

Innsbruck Medical University  
Innsbruck Austria  
*susanne.ebner@i-med.ac.at*

**Monika Enqvist**

Karolinska Institute  
Stockholm Sweden  
*monika.enqvist@ki.se*

**Cornelia Fabritius**

Medical University of Innsbruck  
Innsbruck Austria  
*cornelia.fabritius@i-med.ac.at*

**Leonardo Fainboim**

INIGEM-CONICET/UBA  
Buenos Aires Argentina  
*lfainboim@hospitaldeclinicas.uba.ar*

**Christine Falk**

Hannover Medical School  
Hannover Germany  
*falk.christine@mh-hannover.de*

**Jake Fathman**

Genomics Institute of the Novartis  
Research Foundation  
San Diego USA  
*jfathman@gnf.org*

**Cyril Fauriat**

INSERM U1068  
Marseille France  
*cyril.fauriat@inserm.fr*

**Todd Fehniger**

Washington University School of Medicine  
St Louis USA  
*tfehnige@wustl.edu*

**Martin Felices**

University of Minnesota  
Minneapolis USA  
*mfelices@umn.edu*

**Nathalie Fiegler**

German Cancer Research Centre  
Heidelberg Germany  
*n.fiegler@dkfz.de*

**Jessica Filtjens**

Ghent University  
Ghent Belgium  
*jessica.filtjens@ugent.be*

**Cinzia Fionda**

Sapienza University of Rome  
Rome Italy  
*cinzia.fionda@uniroma1.it*

**Leslie Fogel**

Washington University School of Medicine  
St. Louis USA  
*fogell@wusm.wustl.edu*

**Elin Forslund**

Karolinska Institute  
Stockholm Sweden  
*elin.forslund@ki.se*

**Anthony French**

Washington University St. Louis  
St Louis USA  
*french\_a@kids.wustl.edu*

**Katia Gagne**

Etablissement Français du Sang  
Nantes France  
*katia.gagne@efs.sante.fr*

**Thorsten Gantke**

Affimed Therapeutics AG  
Heidelberg Germany  
*c.heisch@affimed.com*

**Eva Maria Garcia-Cuesta**

National Centre for Biotechnology, CSIC  
Madrid Spain  
*emgarcia@cnb.csic.es*

**M. Isabel Garcia-Laorden**

Academic Medical Center at the  
University of Amsterdam  
Amsterdam Netherlands  
*ihalemgl@yahoo.es*

**Clair Gardiner**

Trinity College  
Dublin Ireland  
*clair.gardiner@tcd.ie*

**Georg Gasteiger**

Sloan-Kettering Institute  
New York USA  
*georg.gasteiger@web.de*

**Daniele Gaudiosi**  
BioRad AbD Serotec Ltd  
Oxon United Kingdom  
*daniele.gaudiosi@abdserotec.com*

**Louise Gaynor**  
University of Cambridge  
Cambridge United Kingdom  
*lmg46@cam.ac.uk*

**Theresa Geiger**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
*geigert@mskcc.org*

**Sabrina Genssler**  
Georg-Speyer-Haus  
Frankfurt am Main Germany  
*genssler@med.uni-frankfurt.de*

**Hormas Ghadially**  
MedImmune Ltd.  
Cambridge United Kingdom  
*ghadiallyh@medimmune.com*

**Kathrin Gibbert**  
University Medical Center Essen  
Essen Germany  
*kathrin.gibbert@uni-due.de*

**Mark Gibson**  
The Pirbright Institute  
Woking United Kingdom  
*mark.gibson@pirbright.ac.uk*

**Mari Gilljam**  
Karolinska Institute  
Stockholm Sweden  
*mari.gilljam@ki.se*

**Ariella Glasner**  
The Hebrew University  
Jerusalem Israel  
*ariella.glasner@gmail.com*

**Timor Glatzer**  
German Rheumatism Research Centre  
Berlin Germany  
*glatzer@drfz.de*

**Thomas Göbel**  
University of Munich  
München Germany  
*goebel@lmu.de*

**Michaela Golic**  
ECRC Experimental and Clinical  
Research Center  
Berlin Germany  
*michaela.golic@charite.de*

**Martin Goodier**  
School of Hygiene and Tropical Medicine  
London United Kingdom  
*martin.goodier@lshtm.ac.uk*

**Markus Granzin**  
Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
*markusgr@miltenyibiotec.de*

**Roger Grau**  
Novartis  
Basel Switzerland  
*roger.grau@novartis.com*

**Catharina Gross**  
University Medical Center Münster  
Münster Germany  
*catharina.gross@ukmuenster.de*

**Ariane Groth**  
Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*groth@med.uni-frankfurt.de*

**Bartosz Grzywacz**  
UW Madison  
Middleton USA  
*bgrzywacz@uwhealth.org*

**Nadia Guerra**  
Imperial College London  
London United Kingdom  
*n.guerra@imperial.ac.uk*

**Fernando Guimarães**  
Campinas University  
Campinas Brazil  
*fernando@caism.unicamp.br*

**Karolin Guldevall**  
Royal Institute of Technology  
Solna Sweden  
*kguldevall@gmail.com*

**Matthew Gumbleton**  
SUNY Upstate Medical University  
Syracuse USA  
*gumbletm@upstate.edu*

**Huaijian Guo**  
Institut de Recherches Cliniques de  
Montréal  
Montreal Canada  
*huaijian.guo@mail.mcgill.ca*

**Wiebke Hamann**  
German Rheumatism Research Centre  
Berlin Germany  
*wiebke.hamann@drfz.de*

**Quirin Hammer**  
German Rheumatism Research Centre  
Berlin Germany  
*quirin.hammer@drfz.de*

**John Hammond**  
Pirbright Institute  
Woking United Kingdom  
*john.hammond@pirbright.ac.uk*

**Stefan Heinz**  
Medicyte GmbH  
Heidelberg Germany  
*s.heinz@medicyte.com*

**Maryam Hejazi**  
University Medical Center Düsseldorf  
Düsseldorf Germany  
*hejazi@itz.uni-duesseldorf.de*

**Werner Held**  
University of Lausanne  
Eplalinges Switzerland  
*werner.held@unil.ch*

**Deborah Hendricks**  
University of California, San Francisco  
San Francisco USA  
*deborah.hendricks@ucsf.edu*

**Julia Hengst**  
Medical School Hannover  
Hannover Germany  
*hengst.julia@mh-hannover.de*

**Julia Herrmann**  
Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*j.herrmann@em.uni-frankfurt.de*

**Erhard Hofer**  
Medical University of Vienna  
Vienna Austria  
*erhard.hofer@meduniwien.ac.at*

**Petter Höglund**  
Karolinska Institute  
Stockholm Sweden  
*petter.hoglund@ki.se*

**Oliver Hölsken**  
German Cancer Research Centre  
Heidelberg Germany  
*o.hoelsken@dkfz.de*

**Katharine Hsu**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
*hsuk@mskcc.org*

**Wei-Chen Huang**  
University College London  
London United Kingdom  
*mail.huangweichen@gmail.com*

**Christian Hüber**  
University of Cambridge  
Cambridge United Kingdom  
*cmh201@cam.ac.uk*

**Volker Huppert**  
Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
*volker@miltenyibiotec.de*

**Marit Inngjerdengen**  
Oslo University Hospital  
Oslo Norway  
*mariti@medisin.uio.no*

**Martin Ivarsson**  
Karolinska Institute  
Stockholm Sweden  
*martin.ivarsson@ki.se*

**Nicola Jackson**  
Anthony Nolan  
London United Kingdom  
*nicola.jackson@anthonymolan.org*

**Roland Jacobs**  
Hannover Medical School  
Hannover Germany  
*jacobs.roland@mh-hannover.de*

**Nathalie Jacobs**  
University of Liege  
Liege Belgium  
*n.jacobs@ulg.ac.be*

**Janine Jahn**  
Martin-Luther-University Halle-Wittenberg  
Halle (Saale) Germany  
*janine.jahn@medizin.uni-halle.de*

**Dasaradha Jalapothu**  
University of Oslo  
Oslo Norway  
*dasaradha.jalapothu@medisin.uio.no*

**Sabelle Jallow**  
Medical Research Council Unit  
Fajara Gambia  
*sabellejallow@yahoo.com*

**Lothar Jänsch**  
Helmholtz Centre for Infection Research  
Braunschweig Germany  
*lothar.jaensch@helmholtz-hzi.de*

**Jessica Jegodka**  
German Cancer Research Center  
Heidelberg Germany  
*j.jegodka@dkfz-heidelberg.de*

**Helle Jensen**  
University of California, San Francisco  
San Francisco USA  
*helle.jensen@ucsf.edu*

**Sofia Johansson**  
Karolinska Institute  
Stockholm Sweden  
*sofia.e.johansson@ki.se*

**Maria H. Johansson**  
Karolinska Institute  
Stockholm Sweden  
*maria.johansson@ki.se*

**Stipan Jonjic**  
Medical Faculty University of Rijeka  
Rijeka Croatia  
*stipan.jonjic@medri.uniri.hr*

**Stephanie Jost**  
Ragon Institute of MGH, MIT and Harvard  
Cambridge USA  
*sjost@partners.org*

**Vanda Juranic Lisnic**  
School of Medicine, University of Rijeka  
Rijeka Croatia  
*vanda.juranic@uniri.hr*

**Nadir Kadri**  
Karolinska Institute  
Stockholm Sweden  
*nadir.kadri@ki.se*

**Christian Kalberer**  
University Medical Center Basel  
Basel Switzerland  
*ckalberer@uhbs.ch*

**Taku Kambayashi**  
University of Pennsylvania  
Philadelphia USA  
*taku.kambayashi@uphs.upenn.edu*

**Kevin Kane**  
University of Alberta  
Edmonton Canada  
*kevin.kane@ualberta.ca*

**Jenny Karo**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
*karoj@mskcc.org*

**Janina Kaudeer**  
Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*kaudeer@em.uni-frankfurt.de*

**Gurman Kaur**  
University of Oxford  
Oxford United Kingdom  
*gurman.kaur@imm.ox.ac.uk*

**Barbara Kee**  
University of Chicago  
Chicago USA  
*bkee@bsd.uchicago.edu*

**Salim Khakoo**  
University of Southampton Faculty of  
Medicine  
Southampton United Kingdom  
*s.i.khakoo@soton.ac.uk*

**Zena Khaznadar**  
Institut universitaire d'hématologie -  
INSERM UMR940  
Paris France  
*zena.khaznadar@gmail.com*

**Jens Kieckbusch**  
University of Cambridge  
Cambridge United Kingdom  
*jk495@cam.ac.uk*

**Rolf Kiessling**  
Karolinska Institute  
Stockholm Sweden  
*rolf.kiessling@ki.se*

**Monica Killig**  
German Rheumatism Research Centre  
Berlin Germany  
*killig@drfz.de*

**Hun Sik Kim**  
University of Ulsan College of Medicine  
Seoul South Korea  
*hunkim@amc.seoul.kr*

**Sang-ki Kim**  
Kongju National University  
Yesan, Chungnam South Korea  
*sangki@kongju.ac.kr*

**Sungjin Kim**  
Michigan State University  
East Lansing USA  
*kimsj@msu.edu*

**Hans Klingemann**  
Conkwest Inc.  
Cardiff-by-the-Sea USA  
*hklingemann@conkwest.com*

**Dominique Knoll**  
University Hospital Erlangen  
Erlangen Germany  
*dominique.knoll@uk-erlangen.de*

**Joachim Koch**  
Georg-Speyer-Haus  
Frankfurt am Main Germany  
*joachim.koch@em.uni-frankfurt.de*

**Samuel Koerner**  
University of Tübingen  
Tübingen Germany  
*samuel.koerner@med.uni-tuebingen.de*

**Holbrook Kohrt**  
Stanford University  
Stanford USA  
*kohrt@stanford.edu*

**Jacki Kornbluth**  
St. Louis University  
St. Louis USA  
*kornblut@slu.edu*

**Christian Körner**  
Ragon Institute of MGH, MIT and Harvard  
Cambridge USA  
*ckorner@partners.org*

**Tomasz Kostrzewski**  
Imperial College London  
Shortlands United Kingdom  
*tomasz.kostrzewski10@imperial.ac.uk*

**Elena Kovalenko**  
Shemyakin-Ovchinnikov Institute of  
Bioorganic Chemistry  
Moscow Russian Federation  
*kovalenelen@gmail.com*

**Anke Kraft**  
Hannover Medical School  
Hannover Germany  
*kraft.anke@mh-hannover.de*

**Stephanie Krieg**  
University Medical Center Erlangen  
Erlangen Germany  
*stephanie.krieg@uk-erlangen.de*

**Joanna Kritikos**  
Karolinska Institute  
Stockholm Sweden  
[joanna.kritikos@ki.se](mailto:joanna.kritikos@ki.se)

**Korbinian Kropp**  
University of Tübingen  
Tübingen Germany  
[korbinian.kropp@med.uni-tuebingen.de](mailto:korbinian.kropp@med.uni-tuebingen.de)

**Konrad Krzewski**  
National Institutes of Health  
Rockville USA  
[krzewskikj@niaid.nih.gov](mailto:krzewskikj@niaid.nih.gov)

**Jürgen Kuball**  
University Medical Center Utrecht  
Utrecht Netherlands  
[j.h.e.kuball@umcutrecht.nl](mailto:j.h.e.kuball@umcutrecht.nl)

**Carsten Kummerow**  
Saarland University  
Homburg Germany  
[carsten.kummerow@uks.eu](mailto:carsten.kummerow@uks.eu)

**Lise Kveberg**  
Oslo University Hospital  
Oslo Norway  
[lise.kveberg@rr-research.no](mailto:lise.kveberg@rr-research.no)

**Lewis Lanier**  
University of California, San Francisco  
San Francisco USA  
[lewis.lanier@ucsf.edu](mailto:lewis.lanier@ucsf.edu)

**Jean-Benoit Le Luduec**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
[leluduej@mskcc.org](mailto:leluduej@mskcc.org)

**Jianmei Leavenworth**  
Dana Farber Cancer Institute  
Boston USA  
[jianmei\\_leavenworth@dfci.harvard.edu](mailto:jianmei_leavenworth@dfci.harvard.edu)

**Georges Leclercq**  
Ghent University  
Ghent Belgium  
[georges.leclercq@ugent.be](mailto:georges.leclercq@ugent.be)

**Amanda Lee**  
McMaster University  
Hamilton Canada  
[leea55@mcmaster.ca](mailto:leea55@mcmaster.ca)

**Seung-Hwan Lee**  
University of Ottawa  
Ottawa Canada  
[seunglee@uottawa.ca](mailto:seunglee@uottawa.ca)

**Dean Lee**  
MD Anderson Cancer Center  
Houston USA  
[dalee@mdanderson.org](mailto:dalee@mdanderson.org)

**Stefan Leibelt**  
University of Frankfurt  
Frankfurt am Main Germany  
[stefan.leibelt@kgu.de](mailto:stefan.leibelt@kgu.de)

**Salomé Leibundgut-Landmann**  
ETH Zürich  
Zürich Switzerland  
[salome.leibundgut@micro.biol.ethz.ch](mailto:salome.leibundgut@micro.biol.ethz.ch)

**Wing Leung**  
St. Jude Children's Research Hospital  
Memphis USA  
[wing.leung@stjude.org](mailto:wing.leung@stjude.org)

**Shushun Li**  
University of Calgary  
Calgary Canada  
[shusli@ucalgary.ca](mailto:shusli@ucalgary.ca)

**Elisabeth Littwitz**  
University Medical Center Essen  
Essen Germany  
[elisabeth.littwitz@uni-due.de](mailto:elisabeth.littwitz@uni-due.de)

**Dongfang Liu**  
Baylor College of Medicine  
Houston USA  
[dongfang.liu@bcm.edu](mailto:dongfang.liu@bcm.edu)

**Scot Liu**  
Genentech  
South San Francisco USA  
[scotli@gene.com](mailto:scotli@gene.com)

**Lisa Liu**  
Karolinska Institute  
Stockholm Sweden  
[lisa.liu@ki.se](mailto:lisa.liu@ki.se)

**Hans-Gustaf Ljunggren**  
Karolinska Institute  
Stockholm Sweden  
[hans-gustaf.ljunggren@ki.se](mailto:hans-gustaf.ljunggren@ki.se)

**Eric Long**  
NIAID-NIH  
Rockville USA  
[elong@nih.gov](mailto:elong@nih.gov)

**Miguel López-Botet**  
University Pompeu Fabra/IMIM  
Foundation  
Barcelona Spain  
[miguel.lopez-botet@upf.edu](mailto:miguel.lopez-botet@upf.edu)

**Sheila Lopez-Cobo**  
National Centre for Biotechnology, CSIC  
Madrid Spain  
[sheila.lopez@cnb.csic.es](mailto:sheila.lopez@cnb.csic.es)

**Silvia Lopez-Lastra**  
Insitut Pasteur  
Paris France  
[silvia.lopez-lastra@pasteur.fr](mailto:silvia.lopez-lastra@pasteur.fr)

**Sandra Lopez-Verges**  
Gorgas Memorial Institute of Health  
Studies  
Panama Panama  
[ivsandal@gmail.com](mailto:ivsandal@gmail.com)

**Claudia Loske**  
Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
[claudial@miltenyibiotec.de](mailto:claudial@miltenyibiotec.de)

**Carmelo Luci**  
CNRS UMR 7275  
Valbonne - Sophia Antipolis France  
[luci@ipmc.cnrs.fr](mailto:luci@ipmc.cnrs.fr)

**Anna Luenemann**  
University of Zurich  
Zurich Switzerland  
[anna.luenemann@bluewin.ch](mailto:anna.luenemann@bluewin.ch)

**Merlin Luetke-Eversloh**  
German Rheumatism Research Centre  
Berlin Germany  
[luetke-eversloh@drfz.de](mailto:luetke-eversloh@drfz.de)

**Andreas Lundqvist**  
Karolinska Institute  
Stockholm Sweden  
[andreas.lundqvist@ki.se](mailto:andreas.lundqvist@ki.se)

**Sebastian Lunemann**  
Hannover Medical School  
Hannover Germany  
[lunemann.sebastian@mh-hannover.de](mailto:lunemann.sebastian@mh-hannover.de)

**Emily Mace**  
Texas Children's Hospital and Baylor  
College of Medicine  
Houston USA  
[mace@bcm.edu](mailto:mace@bcm.edu)

**Sharline Madera**  
Weill Cornell/Rockefeller/Sloan-Kettering  
Institute  
New York USA  
[shm2021@med.cornell.edu](mailto:shm2021@med.cornell.edu)

**Mala Maini**  
University College London  
London United Kingdom  
[m.maini@ucl.ac.uk](mailto:m.maini@ucl.ac.uk)

**Kerstin Mair**  
University of Veterinary Medicine Vienna  
Vienna Austria  
[kerstin.mair@vetmeduni.ac.at](mailto:kerstin.mair@vetmeduni.ac.at)

**Andrew Makrigiannis**  
University of Ottawa  
Ottawa Canada  
[amakrigi@uottawa.ca](mailto:amakrigi@uottawa.ca)

**Karl Johan Malmberg**  
Karolinska Institute  
Stockholm Sweden  
[kalle.malmberg@ki.se](mailto:kalle.malmberg@ki.se)

**Ofer Mandelboim**  
The Hebrew University  
Jerusalem Israel  
[oferm@ekmd.huji.ac.il](mailto:oferm@ekmd.huji.ac.il)

**Angela Manser**  
University Medical Center Düsseldorf  
Düsseldorf Germany  
*manser@itz.uni-duesseldorf.de*

**Antoine Marçais**  
INSERM U1111 CIRI  
Lyon France  
*antoine.marcais@inserm.fr*

**David Margulies**  
NIAID/NIH  
Bethesda USA  
*dhm@nih.gov*

**Roy Mariuzzo**  
University of Maryland  
Rockville United States of America  
*rmariuzz@umd.edu*

**Nicole Marquardt**  
Karolinska Institute  
Stockholm Sweden  
*nicole.marquardt@ki.se*

**Elsa Marquez**  
University of Alberta  
Edmonton Canada  
*emarquez@ualberta.ca*

**Sonya Marshall-Gradisnik**  
Griffith University  
Gold Coast Australia  
*s.marshall-gradisnik@griffith.edu.au*

**Moustapha Mbow**  
Aristide Le Dantec University Hospital  
Dakar Senegal  
*moustaphazero@yahoo.fr*

**Daniel McVicar**  
National Cancer Institute - Frederick  
Frederick USA  
*mcvicard@mail.nih.gov*

**Ramit Mehr**  
Bar-Ilan University  
Ramat-Gan Israel  
*ramit.mehr@biu.ac.il*

**Stefanie Memmer**  
Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*stefanie.memmer@gmx.de*

**Helena Meßlinger**  
University of Erlangen-Nürnberg  
Erlangen Germany  
*helena.messlinger@uk-erlangen.de*

**Jakob Michaelsson**  
Karolinska Institute  
Stockholm Sweden  
*jakob.michaelsson@ki.se*

**Clive M. Michelo**  
St. Radboud University Medical Centre  
Nijmegen Netherlands  
*c.michelo@labgk.umcn.nl*

**Matthias Miller**  
German Cancer Research Center  
Heidelberg Germany  
*m.miller@dkfz.de*

**Jeffrey Miller**  
University of Minnesota  
Minneapolis USA  
*mille011@umn.edu*

**Idan Milo**  
Weizmann Institute of Science  
Rehovot Israel  
*idan.milo@weizmann.ac.il*

**Gundula Min-Oo**  
University of California, San Francisco  
San Francisco USA  
*gundula.min-oo@ucsf.edu*

**Chris Mody**  
University of Calgary  
Calgary Canada  
*cmody@ucalgary.ca*

**Ashley Moffett**  
University of Cambridge  
Cambridge United Kingdom  
*am485@cam.ac.uk*

**Frank Momburg**  
German Cancer Research Center  
Heidelberg Germany  
*f.momburg@dkfz.de*

**Elisa Montaldo**  
University of Genoa  
Genoa Italy  
*montaldo.elisa@gmail.com*

**Catherine Moraetis**  
Edward P. Evans Foundation  
Casanova USA  
*catherine@epefoundation.org*

**Manuela Moraru**  
Hospital Universitario Puerta de Hierro  
Madrid Spain  
*manuelamoraru@gmail.com*

**Alessandro Moretta**  
University of Genoa  
Genoa Italy  
*alemoret@unige.it*

**Maelig Morvan**  
University of California, San Francisco  
San Francisco USA  
*maelig.morvan@ucsf.edu*

**Martha-Lena Mueller**  
Karolinska Institute  
Stockholm Sweden  
*martha-lena.mueller@ki.se*

**Bernadett Mueller**  
Hannover Medical School  
Hannover Germany  
*mueller.bernadett@mh-hannover.de*

**Tiernan Mulrooney**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
*mulroont@mskcc.org*

**Aura Muntasell**  
IMIM (Hospital del Mar Medical Research  
Institute)  
Barcelona Spain  
*amuntasell@imim.es*

**Christian Münz**  
University of Zurich  
Zurich Switzerland  
*christian.muenz@uzh.ch*

**William Murphy**  
University of California, Davis  
Sacramento USA  
*jeathompson@ucdavis.edu*

**Christian Naper**  
Rikshospitalet University Hospital  
Oslo Norway  
*cnaper@medisin.uio.no*

**William Nash**  
University of Virginia  
Charlottesville USA  
*wtn3wq@virginia.edu*

**Petra Netter**  
IfADo  
Dortmund Germany  
*netter@ifado.de*

**Christine Neudoerfl**  
Hannover Medical School  
Hannover Germany  
*neudoerfl.christine@mh-hannover.de*

**Jing Ni**  
German Cancer Research Center  
Heidelberg Germany  
*j.ni@dkfz.de*

**Cait Ni Chorcora**  
Trinity Biomedical Sciences Institute  
Dublin Ireland  
*nichorc@tcd.ie*

**Carolyn Nielsen**  
School of Hygiene and Tropical Medicine  
London United Kingdom  
*carolyn.nielsen@lshtm.ac.uk*

**Pranav Oberoi**  
Georg-Speyer-Haus  
Frankfurt am Main Germany  
*oberoi@em.uni-frankfurt.de*

**Vincent Yi Sheng Oei**  
University of Oslo  
Oslo Norway  
*oeiyishengvincent@gmail.com*

**Sarah Oelsner**  
Georg-Speyer-Haus  
Frankfurt am Main Germany  
*sarah.oelsner@kgu.de*

**Björn Önfelt**  
Karolinska Institute  
Stockholm Sweden  
*bjorn.onfelt@ki.se*

**Jordan Orange**  
Baylor College of Medicine  
Houston USA  
*orange@bcm.edu*

**Markus Osl**  
Medical University of Vienna  
Vienna Austria  
*markus.osl@meduniwien.ac.at*

**Anna Oszmiana**  
Manchester United Kingdom  
*anna.oszmiana@postgrad.manchester.ac.uk*

**Daniela Paclik**  
German Rheumatism Research Centre  
Berlin Germany  
*daniela.paclik@drfz.de*

**Jens Pahl**  
German Cancer Research Center  
Heidelberg Germany  
*j.pahl@dkfz.de*

**Veronique Pascal**  
Novo Nordisk A/S  
Maaloev Denmark  
*veps@novonordisk.com*

**Silke Paust**  
Baylor College of Medicine  
Houston, TX USA  
*silke\_paust@post.harvard.edu*

**Isabela Pedroza**  
University College London  
London United Kingdom  
*regmipe@live.ucl.ac.uk*

**Daniela Pende**  
IRCCS AOU San Martino-IST  
Genoa Italy  
*daniela.pende@istge.it*

**Luis Alberto Perez Quintero**  
Institute de Recherches Cliniques de  
Montreal  
Montreal Canada  
*perezla@ircm.qc.ca*

**Giovanna Peruzzi**  
Sapienza University of Rome  
Rome Italy  
*giovanna.peruzzi@uniroma1.it*

**Matthias Pfeiffer**  
University Children's Hospital Tübingen  
Tübingen Germany  
*matthias.pfeiffer@med.uni-tuebingen.de*

**Sytse Piersma**  
Washington University in St. Louis  
St. Louis USA  
*spiersma@dom.wustl.edu*

**Elke Pogge von Strandmann**  
University Medical Center Cologne  
Cologne Germany  
*elke.pogge@uk-koeln.de*

**Julia Pollmann**  
German Cancer Research Centre  
Heidelberg Germany  
*j.pollmann@dkfz.de*

**Andrea Ponzetta**  
Sapienza University of Rome  
Rome Italy  
*andrea.ponzetta@uniroma1.it*

**Angel Porgador**  
Ben-Gurion University of the Negev  
Beer Sheva Israel  
*angel@bgu.ac.il*

**Mirte Post**  
Medical University of Vienna  
Vienna Austria  
*mirte.post@meduniwien.ac.at*

**Henk-Jan Prins**  
Leiden University Medical Center  
Leiden Netherlands  
*h.prins@lumc.nl*

**Martin Prlic**  
Fred Hutchinson Cancer Res. Center  
Seattle USA  
*mprlic@fhcrc.org*

**Gisella Puga Yung**  
University Hospital and Medical Faculty  
Geneva  
Geneva Switzerland  
*gisella.pugayung@hcuge.ch*

**Aldi Pupuleku**  
Pompeu Fabra University Barcelona  
Barcelona Spain  
*aldi.pupuleku@upf.edu*

**Bin Qu**  
Saarland University  
Homburg Germany  
*bin.qu@uks.eu*

**Christian Quack**  
German Cancer Research Centre  
Heidelberg Germany  
*c.quack@dkfz.de*

**Linda Quatrini**  
Sapienza University of Rome  
Rome Italy  
*linda.quatrini@uniroma1.it*

**Stefanie Raab**  
University of Tübingen  
Tübingen Germany  
*stefanie.raab@med.uni-tuebingen.de*

**Sumi Rajagopalan**  
National Institutes of Health  
Rockville USA  
*sumi@nih.gov*

**Orhan Rasiid**  
Institut Pasteur  
Paris France  
*orhan.rasiid@gmail.com*

**David Raulet**  
University of California, Berkeley  
Berkeley USA  
*raulet@berkeley.edu*

**Katrin Reiners**  
University Medical Center Cologne  
Köln Germany  
*katrin.reiners@uk-koeln.de*

**Simone Reipschläger**  
IfADo  
Dortmund Germany  
*reipschlaeger@ifado.de*

**Virginie Renoux**  
Lund University  
Lund Sweden  
*virginie.renoux@med.lu.se*

**Christelle Retiere**  
Etablissement Français du Sang  
Nantes France  
*christelle.retiere@efs.sante.fr*

**Uwe Reusch**  
Affimed Therapeutics AG  
Heidelberg Germany  
*u.reusch@affimed.com*

**Hugh Reyburn**  
National Centre for Biotechnology, CSIC  
Madrid Spain  
*htreyburn@cnb.csic.es*

**Biancamaria Ricci**  
Sapienza University of Rome  
Rome Italy  
*biancamaria.ricci@uniroma1.it*

**Peggy Riese**  
Helmholtz Centre for Infection Research  
Braunschweig Germany  
*peggy.riese@helmholtz-hzi.de*

**Rebecka Riise**  
Sahlgrenska Cancer Centre  
Gothenburg Sweden  
*rebecca.riise@gmail.com*

**Eleanor Riley**  
School of Hygiene and Tropical Medicine  
London United Kingdom  
*eleanor.riley@lshtm.ac.uk*

**Kimberly Risma**  
Cincinnati Children's Hospital Medical  
Center  
Cincinnati USA  
*kimberly.risma@cchmc.org*

**Alexander Rölle**  
German Cancer Research Center  
Heidelberg Germany  
*a.roelle@dkfz-heidelberg.de*

**Bent Rolstad**  
University of Oslo  
Oslo Norway  
*bent.rolstad@medisin.uio.no*

**Chiara Romagnani**  
German Rheumatism Research Centre  
Berlin Germany  
*romagnani@drfz.de*

**John Rømer**  
Novo Nordisk A/S  
Maaloev Denmark  
*jorm@novonordisk.com*

**Eddy Roosnek**  
Geneva University Hospitals and  
University of Geneva  
Geneva Switzerland  
*eddy.roosnek@unige.ch*

**Jay Ryan**  
University California San Francisco  
San Francisco United States of America  
*james.ryan@va.gov*

**Per Christian Saether**  
University of Oslo  
Oslo Norway  
*p.c.sather@medisin.uio.no*

**Sadia Salam**  
Karolinska Institute  
Stockholm Sweden  
*sadiarana@gmail.com*

**Helmut Salih**  
University of Tübingen  
Tübingen Germany  
*helmut.salih@med.uni-tuebingen.de*

**Mina Sandusky**  
IfADo  
Dortmund Germany  
*sandusky@ifado.de*

**Angela Santoni**  
Sapienza University of Rome  
Rome Italy  
*angela.santoni@uniroma1.it*

**Dhifaf Sarhan**  
Karolinska Institute  
Stockholm Sweden  
*dhifaf.sarhan@ki.se*

**Aurore Saudemont**  
Anthony Nolan / University College  
London  
London United Kingdom  
*aurore.saudemont@anthonymolan.org*

**Maike Sauer**  
University Medical Center Cologne  
Cologne Germany  
*maikesauer@googlemail.com*

**Jamie Schafer**  
Harvard University  
Southborough USA  
*jschafer@fas.harvard.edu*

**Maxi Scheiter**  
Helmholtz Centre for Infection Research  
Braunschweig Germany  
*maxi.scheiter@helmholtz-hzi.de*

**Marco Schilham**  
Leiden University Medical Center  
Leiden Netherlands  
*m.w.schilham@lumc.nl*

**Eva Schlecker**  
German Cancer Research Center  
Heidelberg Germany  
*e.schlecker@dkfz.de*

**Patrick Schlegel**  
University Children's Hospital Tuebingen  
Tuebingen Germany  
*patrick.schlegel@med.uni-tuebingen.de*

**Heinrich Schlums**  
Karolinska Institute  
Stockholm Sweden  
*heinrich.schlums@ki.se*

**Laurent Schmied**  
University Medical Center Basel  
Basel Switzerland  
*laurent.schmied@unibas.ch*

**Dominik Schmiedel**  
Institute for Medical Research Israel  
Canada (IMRIC)  
Jerusalem Israel  
*dominik.schmiedel@gmx.de*

**Juergen Schmitz**  
Miltenyi Biotec GmbH  
Bergisch Gladbach Germany  
*juergens@miltenyibiotec.de*

**E. Marion Schneider**  
University Medical Center Ulm  
Ulm Germany  
*marion.schneider@uni-ulm.de*

**Kathrin Schönberg**  
University Medical Center Bonn  
Bonn Germany  
*kathrin.schoenberg@ukb.uni-bonn.de*

**William Seaman**  
University of California, San Francisco  
San Francisco USA  
*bseaman@medicine.ucsf.edu*

**Jörg D. Seebach**  
University Hospitals Geneva  
Geneva Switzerland  
*joerg.seebach@hcuge.ch*

**Andrew Sharkey**  
University of Cambridge  
Cambridge United Kingdom  
*as168@cam.ac.uk*

**Sam Sheppard**  
Imperial College London  
London United Kingdom  
*sam.sheppard09@imperial.ac.uk*

**Uwe Siegler**  
University Medical Center Basel  
Basel Switzerland  
*uwe.siegler@usb.ch*

**Luis Sigal**  
Fox Chase Cancer Center  
Philadelphia USA  
*luis.sigal@fccc.edu*

**Ewa Sitnicka**  
Stem Cell Center, Lund University  
Lund Sweden  
*ewa.sitnicka@med.lu.se*

**Marwan Sleiman**  
CRP-Sante  
Luxembourg Luxembourg  
*marwan.sleiman@crp-sante.lu*

**Dorothy Sojka**  
Washington University  
St. Louis USA  
*dsojka@dom.wustl.edu*

**Fernando Souza-Fonseca-Guimaraes**  
Queensland Institute of Medical Research  
Brisbane Australia  
*fernando.guimaraes@qimr.edu.au*

**Roberto Spada**  
National Centre for Biotechnology, CSIC  
Madrid Spain  
*rspada@cnb.csic.es*

**Jan Spanholtz**  
Glycostem Therapeutics  
s-Hertogenbosch Netherlands  
*jan.spanholtz@glycostem.com*

**Hergen Spits**  
AMC at the University of Amsterdam  
Amsterdam Netherlands  
*hergen.spits@amc.uva.nl*

**Kerstin Stegmann**  
London School of Hygiene and Tropical  
Medicine  
London United Kingdom  
*kerstin.stegmann@lshtm.ac.uk*

**Alexander Steinle**  
University of Frankfurt  
Frankfurt am Main Germany  
*alexander.steinle@kgu.de*

**Birgitta Stellan**  
Karolinska Institute  
Stockholm Sweden  
*birgitta.stellan@ki.se*

**Martin Stern**  
University Medical Center Basel  
Basel Switzerland  
*martin.stern@usb.ch*

**Ana Stojanovic**  
German Cancer Research Centre  
Heidelberg Germany  
[a.stojanovic@dkfz.de](mailto:a.stojanovic@dkfz.de)

**Elisabeth Straka**  
University of Veterinary Medicine, Vienna  
Vienna Austria  
[strakae@staff.vetmeduni.ac.at](mailto:strakae@staff.vetmeduni.ac.at)

**Marion Subklewe**  
Med. Klinik und Poliklinik III  
München Germany  
[marion.subklewe@med.uni-muenchen.de](mailto:marion.subklewe@med.uni-muenchen.de)

**Garnet Suck**  
German Red Cross  
Berlin Germany  
[g.suck@blutspende.de](mailto:g.suck@blutspende.de)

**Amanda Sudworth**  
University of Oslo  
Oslo Norway  
[amandasu@ulrik.uio.no](mailto:amandasu@ulrik.uio.no)

**Joseph Sun**  
Memorial Sloan-Kettering Cancer Center  
New York USA  
[sunj@mskcc.org](mailto:sunj@mskcc.org)

**Srividya Sundararaman**  
Cellular Technology Ltd.  
Shaker Heights USA  
[srividya.sundararaman@immunospot.com](mailto:srividya.sundararaman@immunospot.com)

**Tolga Sutlu**  
Karolinska Institute  
Huddinge Sweden  
[tolga.sutlu@ki.se](mailto:tolga.sutlu@ki.se)

**Duangchan Suwannasaen**  
St. Jude Children's Research Hospital  
Memphis USA  
[duangchan.suwannasaen@stjude.org](mailto:duangchan.suwannasaen@stjude.org)

**Thomas Tan**  
University of Cambridge  
Cambridge United Kingdom  
[tct23@cam.ac.uk](mailto:tct23@cam.ac.uk)

**Sylvie Taveirne**  
Ghent University  
Ghent Belgium  
[sylvie.taveirne@ugent.be](mailto:sylvie.taveirne@ugent.be)

**Karin Tennert**  
University Medical Center Erlangen  
Erlangen Germany  
[karin.tennert@gmx.de](mailto:karin.tennert@gmx.de)

**Jeffrey Teoh**  
University of Virginia  
Charlottesville USA  
[jjt8vb@virginia.edu](mailto:jjt8vb@virginia.edu)

**Grzegorz Terszowski**  
University Medical Center Basel  
Basel Switzerland  
[grzegorz.terszowski@unibas.ch](mailto:grzegorz.terszowski@unibas.ch)

**Hiroshi Terunuma**  
Biotherapy Institute of Japan  
Tokyo Japan  
[terunuma.h@gmail.com](mailto:terunuma.h@gmail.com)

**Lavanya Thiruchelvam-Kyle**  
University of Oslo  
Oslo Norway  
[lavanyt@gmail.com](mailto:lavanyt@gmail.com)

**Fredrik B. Thorén**  
University of Gothenburg  
Gothenburg Sweden  
[fredrik.thoren@gu.se](mailto:fredrik.thoren@gu.se)

**Zhigang Tian**  
University of Science and Technology of  
China  
Hefei China  
[tzg@ustc.edu.cn](mailto:tzg@ustc.edu.cn)

**Sara Tognarelli**  
University Medical Center Frankfurt  
Frankfurt am Main Germany  
[sara.tognarelli@kgu.de](mailto:sara.tognarelli@kgu.de)

**Giovanni Torelli**  
Azienda Policlinico Umberto I  
Rome Italy  
[alessandrag@miltenyibiotec.it](mailto:alessandrag@miltenyibiotec.it)

**Sandeep Tripathy**  
Washington University School of  
Medicine  
Saint Louis USA  
[stripath@dom.wustl.edu](mailto:stripath@dom.wustl.edu)

**John Trowsdale**  
University of Cambridge  
Cambridge United Kingdom  
[jt233@cam.ac.uk](mailto:jt233@cam.ac.uk)

**Tihana Trsan**  
Faculty of Medicine, University of Rijeka  
Rijeka Croatia  
[tihana.trsan@gmail.com](mailto:tihana.trsan@gmail.com)

**Dejene Milkessa Tufa**  
Hannover Medical School  
Hannover Germany  
[tufa.dejene@mh-hannover.de](mailto:tufa.dejene@mh-hannover.de)

**Markus Uhrberg**  
University of Düsseldorf  
Düsseldorf Germany  
[uhrberg@itz.uni-duesseldorf.de](mailto:uhrberg@itz.uni-duesseldorf.de)

**Evelyn Ullrich**  
University of Frankfurt  
Frankfurt am Main Germany  
[evelyn.ullrich@kgu.de](mailto:evelyn.ullrich@kgu.de)

**Doris Urlaub**  
IfADo  
Dortmund Germany  
[urlaub@ifado.de](mailto:urlaub@ifado.de)

**Aline van Acker**  
Ghent University  
Ghent Belgium  
[aline.vanacker@ugent.be](mailto:aline.vanacker@ugent.be)

**Kattia van der Ploeg**  
University of Cambridge  
Cambridge United Kingdom  
[kv279@cam.ac.uk](mailto:kv279@cam.ac.uk)

**Michel van Gelder**  
Maastricht University Medical Center  
Maastricht Netherlands  
[m.van.gelder@mumc.nl](mailto:m.van.gelder@mumc.nl)

**Mandy van Hees**  
Ghent University  
Ghent Belgium  
[mandy.vanhees@ugent.be](mailto:mandy.vanhees@ugent.be)

**Mary van Helden**  
VIB  
Ghent Belgium  
[maryvh@dibr.vib-ugent.be](mailto:maryvh@dibr.vib-ugent.be)

**Ramakrishna Vankayalapati**  
University of Texas Health Science  
Center at Tyler  
Tyler USA  
[krishna.vankayalapati@uthct.edu](mailto:krishna.vankayalapati@uthct.edu)

**André Veillette**  
Institut de Recherches Cliniques de  
Montréal  
Montreal Canada  
[andre.veillette@ircm.qc.ca](mailto:andre.veillette@ircm.qc.ca)

**John Veluchamy**  
VU University Medical Center Amsterdam  
Amsterdam Netherlands  
[john.veluchamy@glycostem.com](mailto:john.veluchamy@glycostem.com)

**Michael Verneris**  
University of Minnesota  
Minneapolis USA  
[verneris@umn.edu](mailto:verneris@umn.edu)

**Vincent Vieillard**  
INSERM UMR-S 945  
Paris France  
[vincent.vieillard@upmc.fr](mailto:vincent.vieillard@upmc.fr)

**Birgit Viertlboeck**  
University of Munich  
Munich Germany  
[birgit.viertlboeck@imu.de](mailto:birgit.viertlboeck@imu.de)

**Carlos Vilches**  
Hospital Universitario Puerta de Hierro  
Majadahonda Spain  
[carlos.vilches@yahoo.com](mailto:carlos.vilches@yahoo.com)

**Jean Villard**  
Geneva University Hospital  
Geneva Switzerland  
[jean.villard@hcuge.ch](mailto:jean.villard@hcuge.ch)

**Eric Vivier**  
Aix Marseille University  
Marseille France  
[vivier@ciml.univ-mrs.fr](mailto:vivier@ciml.univ-mrs.fr)

**Benjamin Vogel**  
University Medical Center Erlangen  
Erlangen Germany  
[bnvogel@viro.med.uni-erlangen.de](mailto:bnvogel@viro.med.uni-erlangen.de)

**Jenny Voigt**

Helmholtz Centre for Infection Research  
Braunschweig Germany  
*jenny.voigt@helmholtz-hzi.de*

**Ilia Voskoboinik**

Peter MacCallum Cancer Centre  
East Melbourne Australia  
*ilia.voskoboinik@petermac.org*

**Christian Vosshenrich**

Institut Pasteur  
Paris France  
*christian.vosshenrich@pasteur.fr*

**Alexandra Vrazo**

Cincinnati Children's Hospital Medical  
Center  
Cincinnati USA  
*alexandra.vrazo@cchmc.org*

**Stephen Waggoner**

Cincinnati Children's Hospital Medical  
Center  
Cincinnati USA  
*stephen.waggoner@cchmc.org*

**Arnika Wagner**

Karolinska Institute  
Stockholm Sweden  
*arnika.wagner@ki.se*

**Lutz Walter**

German Primate Center  
Göttingen Germany  
*walter@dpz.eu*

**Thierry Walzer**

Centre International d'Infectiologie  
Lyon France  
*thierry.walzer@inserm.fr*

**Xi Wang**

Tianjin Medical University  
Tianjin China  
*wangxi@tjmu.edu.cn*

**Carsten Watzl**

IfADo  
Dortmund Germany  
*watzl@ifado.de*

**Hans Heinrich Wedemeyer**

Hannover Medical School  
Hannover Germany  
*wedemeyer.heiner@mh-hannover.de*

**Sandra Weil**

Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*s.weil@em.uni-frankfurt.de*

**Winfried Wels**

Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*wels@em.uni-frankfurt.de*

**Raymond Welsh**

University of Massachusetts Medical  
School  
Worcester USA  
*raymond.welsh@umassmed.edu*

**Susanne Wendt**

St. Jude Children's Research Hospital  
Memphis USA  
*susanne.wendt@stjude.org*

**Laura Wetherill**

University of Leeds  
Leeds United Kingdom  
*l.f.wetherill@leeds.ac.uk*

**Matthew White**

London School of Hygiene and Tropical  
Medicine  
London United Kingdom  
*matthew.white@lshtm.ac.uk*

**Stina Wickström**

Karolinska Institute  
Stockholm Sweden  
*stina.wickstrom@ki.se*

**Julia Wild**

University of Tübingen  
Tübingen Germany  
*julia.wild@med.uni-tuebingen.de*

**Esther Wilk**

Helmholtz Centre for Infection Research  
Braunschweig Germany  
*ewi09@helmholtz-hzi.de*

**Erica Wilson**

University of Leeds  
Leeds United Kingdom  
*e.wilson@leeds.ac.uk*

**Sabine Wingert**

IfADo  
Dortmund Germany  
*wingert@ifado.de*

**Agnieszka Witalisz**

University of Veterinary Medicine  
Vienna Austria  
*agnieszka.witalisz@vetmeduni.ac.at*

**Asia-Sophia Wolf**

London School of Hygiene and Tropical  
Medicine  
London United Kingdom  
*asia-sophia.wolf@lshtm.ac.uk*

**Zeguang Wu**

University Medical Center Ulm  
Ulm Germany  
*zeguang.wu@uni-ulm.de*

**EnJun Yang**

University of Pennsylvania  
Philadelphia USA  
*enjoyang@mail.med.upenn.edu*

**Meixiang Yang**

Tsinghua University  
Beijing China  
*ustcdzj@yahoo.com*

**Wayne Yokoyama**

Washington University/HHMI  
St. Louis USA  
*yokoyama@dom.wustl.edu*

**Jianhua Yu**

The Ohio State University  
Columbus USA  
*jianhua.yu@osumc.edu*

**Biljana Zafirova**

Institut Pasteur  
Paris France  
*biljazaf@pasteur.fr*

**Gulnur Zakiryanova**

Institute of Molecular Biology  
Almaty Kazakhstan  
*gzakiryanova@gmail.com*

**Loris Zamai**

University of Urbino  
Urbino Italy  
*loris.zamai@uniurb.it*

**Congcong Zhang**

Intitute for Biomedical Research Georg-  
Speyer-Haus  
Frankfurt am Main Germany  
*c.zhang@med.uni-frankfurt.de*

**Eugene Zhukovsky**

Affimed Therapeutics  
Heidelberg Germany  
*e.zhukovsky@affimed.com*

**Jacques Zimmer**

Centre de Recherche Public de la Santé  
(CRP-Santé)  
Luxembourg Luxembourg  
*jacques.zimmer@crp-sante.lu*

**Laurence Zitvogel**

Institut de Cancérologie Gustave Roussy  
(IGR)  
Villejuif France  
*laurence.zitvogel@wanadoo.fr*



## NK2013 – Program at a glance

Time	17.9.13	18.9.13	19.9.13	20.9.13	21.9.13	Time	
9.00		Arrival and registration	NK cell education and function	NK subsets and memory	Innate lymphoid cells and decidal NK cells	9.00	
9.30			Coffee break	Coffee break	Coffee break	9.30	
10.00				NK receptors and signaling	NK cells and viral immunity	NK cells and viral immunity	10.00
10.30				Lunch	Lunch	Lunch	10.30
11.00	Registration		Meet the speaker I	Meet the speaker II	Meet the speaker III	11.00	
11.30						11.30	
12.00							12.00
12.30	Workshop: "NK cells in clinical application: experiences and perspectives"	Welcome and Keynote	Lunch	Lunch	Lunch	12.30	
13.00						13.00	
13.30							13.30
14.00							14.00
14.30							14.30
15.00			NK receptors and signaling	NK cells and cancer	NK cell function and dysfunction	15.00	
15.30		Coffee break	Free time/networking	Free time/networking	Coffee break	15.30	
16.00		NK cell development, education and differentiation	Tutorial: Mathematical modeling	Career session	NK cells and infection	16.00	
16.30		Welcome reception dinner				16.30	
17.00							17.00
17.30			Dinner	Dinner	Free time/networking	17.30	
18.00						18.00	
18.30						18.30	
19.00						19.00	
19.30			Poster session 1 Open bar	Poster session 2 Open bar	Gala dinner (castle)	19.30	
20.00						20.00	
20.30						20.30	
21.00						21.00	